



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48, 9/127, 41/00		A2	(11) International Publication Number: WO 97/46262 (43) International Publication Date: 11 December 1997 (11.12.97)
(21) International Application Number: PCT/US97/09501 (22) International Filing Date: 4 June 1997 (04.06.97) (30) Priority Data: 08/657,947 4 June 1996 (04.06.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CP, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicants (for all designated States except US): PHARMACYCLICS, INC. [US/US]; 995 East Arques Avenue, Sunnyvale, CA 94086-4521 (US). BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): YOUNG, Stuart, W. [US/US]; 45 Las Piedras, Portola, CA 94028 (US). WRIGHT, Meredith [US/US]; 1057 Ginger Lane, San Jose, CA 95128 (US). SESSLER, Jonathan, L. [US/US]; 5005 Crestway Drive, Austin, TX 78712 (US). MODY, Tarak, D. [US/US]; 243 Buena Vista Avenue #206, Sunnyvale, CA 94086 (US). MAGDA, Darren [US/US]; 10237 University Way, Cupertino, CA 95014 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(74) Agent: NORBERG, Gloria, L.; Akin, Gump, Strauss, Hauer & Feld, L.L.P., Suite 1900, 816 Congress Avenue, Austin, TX 78701 (US).			
(54) Title: MEMBRANE INCORPORATION OF TEXAPHYRINS			
(57) Abstract <p>Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen. By presenting the agent in this way, it is expected that a patient will experience less toxicity.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MN	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

MEMBRANE INCORPORATION OF TEXAPHYRINS

10 BACKGROUND OF THE INVENTION

A drug delivery system should deliver drug at a rate dictated by the needs of a medical procedure over the period of the procedure, that is, the goal of any drug delivery system is to provide a therapeutic amount of drug to the proper site in the body to promptly achieve, and then maintain, the desired drug concentration. This objective 15 emphasizes the need for spatial placement and temporal delivery of a drug or treatment. Spatial placement is the targeting of a drug to a specific organ, tissue, or bodily system such as the blood stream; while temporal delivery refers to controlling the rate of drug delivery to the target.

Targeted drug delivery systems include colloidal drug delivery systems and 20 resealed or modified cells, for example, resealed or modified erythrocytes or leukocytes. Colloidal drug delivery systems include nanoparticles, microcapsules, nanocapsules, macromolecular complexes, polymeric beads, microspheres, liposomes, and lipid vesicles.

Liposomes are formed from phospholipids that are dispersed in an aqueous 25 medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)). MLVs generally have diameters of from 4 mm to 25 nm. Sonication or solvent dilution of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 300 to 500 Å.

Liposomes resemble cellular membranes, and water- or lipid-soluble substances 30 can be entrapped in the aqueous spaces or within the bilayer, respectively. An important determinant in entrapping compounds is the physicochemical properties of the compound itself. Polar compounds are trapped in the aqueous spaces and are released through permeation or when the bilayer is broken; nonpolar compounds bind to the lipid bilayer of the vesicle, and tend to remain there unless the bilayer is disrupted 35 by temperature or exposure to lipoproteins.

Liposomes may interact with cells via a number of different mechanisms, for example: endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface

5 components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; or by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without any association of the liposome contents. It often is difficult to determine which mechanism is operative and more than one may operate at

10 the same time.

Intravenously injected liposomes may persist in tissues for hours or days, depending on their composition, and half-lives in the blood range from minutes to several hours. Larger liposomes are taken up rapidly by phagocytic cells of the reticuloendothelial system and exit only in places where large openings or pores exist in

15 the capillary endothelium, such as the sinusoids of the liver or spleen. Thus, these organs are the predominant site of uptake. On the other hand, smaller liposomes show a broader tissue distribution but still are sequestered highly in the liver and spleen. In general, this *in vivo* behavior limits the potential targeting of liposomes to only those organs and tissues accessible to their large size. These include the blood, liver, spleen,

20 bone marrow and lymphoid organs.

Attempts to overcome the limitation on targeting of liposomes have centered around two approaches. One is the use of antibodies, bound to the liposome surface, to direct the antibody and the liposome contents to specific antigenic receptors located on a particular cell-type surface. Further, carbohydrate determinants (glycoprotein or

25 glycolipid cell-surface components that play a role in cell-cell recognition, interaction and adhesion) may also be used as recognition sites since they have potential in directing liposomes to particular cell types.

Further lipid vesicles, such as nonphospholipid paucilamellar lipid vesicles (PLV's), are made from materials such as polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamines, long-chain acyl amino acid amides, long-chain acyl amides, polyoxyethylene sorbitan mono and tristearates and oleates, polyoxyethylene glyceryl monostearates and monooleates, and glyceryl monostearates and monooleates, (U.S. Patents 4,911,928, 4,917,951, and 5,000,960).

Resealed erythrocytes are another form of targeted drug delivery. When

30 erythrocytes are suspended in a hypotonic medium, they swell to about one and a half times their normal size, and the membrane weakens, resulting in the formation of small pores. The pores allow equilibration of the intracellular and extracellular solutions. If

5 the ionic strength of the medium then is adjusted to isotonicity, the pores will close and cause the membrane of the erythrocyte to return to normal or "reseal". Using this technique with a drug present in the extracellular solution, it is possible to entrap a substantial amount of the drug inside the resealed erythrocyte and to use this system for targeted delivery via intravenous injection.

10 Studies on the behavior of normal and modified reinfused erythrocytes indicate that, in general, normal aging erythrocytes, slightly damaged erythrocytes and those coated lightly with antibodies are sequestered in the spleen after intravenous reinfusion; but heavily damaged or modified erythrocytes are removed from the circulation by the liver. This suggests that resealed erythrocytes can be targeted selectively to either the 15 liver or spleen, which can be viewed as a disadvantage in that other organs and tissues are inaccessible. Thus, the application of this system to targeted delivery has been limited mainly to treatment of lysosomal storage diseases and metal toxicity, where the site of drug action is in the reticuloendothelial system.

16 Labeling of red blood cells with chromium-51 and white blood cells with indium-111, as well as labeling of liposomes with contrast media and therapeutic agents is known. U.S. Patent 5,466,438 relates to liposoluble complexes of paramagnetic ions and compounds bearing long acyl chains useful as magnetic resonance imaging contrast agents. U.S. Patent 5,000,960 relates to coupling a molecule having a free sulphydryl group to a lipid vesicle having a free sulphydryl group incorporated as one of the 20 structural molecules of the lipid phase thereby forming a covalent disulfide bond linkage. U.S. Patent 4,931,276 relates to methods for introducing desired agents into red blood cells, and U.S. Patent 4,478,824 relates to methods and apparatus for causing reversible intracellular hypertonicity in red blood cells of mammals in order to introduce desired materials into the cells, or achieve therapeutically desirable changes in the 25 characteristics of intracellular hemoglobin. Further, poor accumulation of liposomal cadmium-texaphyrin in tumor tissue was cited as a possible explanation for low efficiency of photodynamic therapy in König *et al.*, (*Lasers in Surgery and Medicine* 13:522, 1993; in: *Photodynamic Therapy and Biomedical Lasers*, P. Spinelli, M. Dal Fante and R. Marchesini, eds., Elsevier Science Publishers, 1992, 802).

30 35 Photodynamic therapy (PDT) is a treatment technique that uses a photosensitizing dye that produces cytotoxic materials, such as singlet oxygen ($O_2(^1D_g)$) from benign precursors (e.g. ($O_2(^3S_g^-)$)), when irradiated in the presence of oxygen.

5 Other reactive species such as superoxide, hydroperoxyl, or hydroxyl radicals may be involved. At the doses used, neither the light nor the drug has any independent activity against the disease target.

10 The effectiveness of PDT is predicated on three main factors: i) The photosensitive dyes used in PDT preferably have the ability to localize at the treatment site as opposed to surrounding tissue. ii) The high reactivity and short lifetime of activated oxygen means that it has a very short range and is unlikely to escape from the cell in which it is produced; cytotoxicity is therefore restricted to the precise region of photoactivated drug. iii) Developments in light delivery, such as lasers, light emitting diodes, and fiber optics, allow a beam of intense light to be delivered accurately to many 15 parts of the body.

20 In recent years, considerable effort has been devoted to the synthesis and study of new photosensitizers (a review is found in Brown, S.B. and Truscott, T.G., 1993, *Chemistry in Britain*, 955-958). The development of more effective photochemotherapeutic agents requires the synthesis of compounds which absorb in the spectral region where living tissues are relatively transparent (i.e., 700-1000 nm), have high triplet quantum yields, are minimally toxic, and have physiologically acceptable water/lipid partition coefficients. Texaphyrins have proven to be effective sensitizers for generating singlet oxygen and for photodynamic therapy (U.S. Patents 5,272,142; 5,292,414; 5,439,570; and 5,451,576, incorporated by reference herein).

25 Magnetic resonance imaging has become an important diagnostic tool in medicine, especially for tumor imaging. Imaging of tissue is dependent upon a difference in the relaxation rates of nuclear spins of water protons from various tissues in a magnetic field. The relaxation rate can be enhanced by use of a contrast agent, thereby improving a resulting image. The gadolinium cation is a superior contrast agent 30 due to its seven unpaired f-electrons and high magnetic moment. However, gadolinium cation is too toxic to be used directly for imaging at concentrations required for effective enhancement. Texaphyrins bind the gadolinium ion in a stable manner and have proved to be nontoxic and effective contrast agents for imaging (U.S. Patents 5,252,720, 5,451,576, and 5,256,399, incorporated by reference herein). Further 35 development of texaphyrin-based magnetic resonance imaging protocols would be of significant value for the improvement of medical diagnostic imaging.

5 Macular degeneration due to damage or breakdown of the macula, underlying tissue, or adjacent tissue is the leading cause of decreased visual acuity and impairment of reading and fine "close-up" vision. Age-related macular degeneration (ARMD) is the major cause of severe visual loss in the elderly. The most common form of macular degeneration is called "dry" or involutional macular degeneration and results from the
10 thinning of vascular and other structural or nutritional tissues underlying the retina in the macular region. A more severe form is termed "wet" or exudative macular degeneration. In this form, blood vessels in the choroidal layer (a layer underneath the retina and providing nourishment to the retina) break through a thin protective layer between the two tissues. These blood vessels may grow abnormally directly beneath the
15 retina in a rapid uncontrolled fashion; resulting in oozing, bleeding, or eventually scar tissue formation in the macula which leads to severe loss of central vision. This process is termed choroidal neovascularization.

Neovascularization results in visual loss in other eye diseases including neovascular glaucoma, ocular histoplasmosis syndrome, myopia, diabetes, pterygium, and infectious and inflammatory diseases. In histoplasmosis syndrome, a series of events occur in the choroidal layer of the inside lining of the back of the eye resulting in localized inflammation of the choroid and consequent scarring with loss of function of the involved retina and production of a blind spot (scotoma). In some cases, the choroid layer is provoked to produce new blood vessels that are much more fragile than normal
20 blood vessels. They have a tendency to bleed with additional scarring, and loss of function of the overlying retina. Diabetic retinopathy involves retinal rather than choroidal blood vessels resulting in hemorrhages, vascular irregularities, and whitish exudates. Retinal neovascularization may occur in the most severe forms.

Current diagnosis of ocular disorders often includes use of a fluorescein or
30 indocyanine green angiogram. In this procedure, the dye is injected into the blood stream through a vein in the arm. Special filters are placed in the light path, and in front of the film, to permit only the fluorescent dye to be seen as it passes through the vessels in the retina. Pictures of the vascular anatomy are taken of the retina and macula as the dye passes through the blood vessels of the back of the eye. Vascular occlusions or
35 leakage of dye indicates abnormal vasculature. Optical coherence tomography is another technique that uses noncontact imaging and provides high-depth resolution in cross-sectional tomographs of the retina.

5 Current treatment of neovascularization relies on ablation of blood vessels using laser photocoagulation. However, such treatment requires thermal destruction of the tissue, and is accompanied by full-thickness retinal damage, as well as damage to medium and large choroidal vessels. Further, the patient is left with an atrophic scar and visual scotoma. Moreover, recurrences are common, and the prognosis for the
10 patient's condition is poor.

Developing strategies, such as PDT, have sought more selective closure of the blood vessels to preserve the overlying neurosensory retina. PDT of conditions in the eye characterized by neovascularization has been attempted using the conventional porphyrin derivatives such as hematoporphyrin derivative and PHOTOFRIN® porfimer sodium. Problems have been encountered in this context due to interference from eye pigments. In addition, phthalocyanine and benzoporphyrin derivatives have been used in photodynamic treatment. PCT publication WO 95 24930 and Miller *et al.*, (*Archives of Ophthalmology*, June, 1995) relate to treatment of eye conditions characterized by unwanted neovasculation comprising administering a green porphyrin to the
15 neovasculation and irradiating the neovasculation with light having a wavelength of 550-695 nm. U.S. Patent 5,166,197 relates to phthalocyanine derivatives reportedly useful for macular degeneration. Asrani and Zeimer (*British Journal of Ophthalmology*, 1995, 79:766-770) relate to photoocclusion of ocular vessels using a phthalocyanine encapsulated in heat-sensitive liposomes. Levy (*Semin. Oncol.* 1994, 21/6, suppl. 15 (4-
20 10)) relates to photodynamic therapy and macular degeneration with porfimer sodium (PHOTOFRIN®, requiring light of 630 nm and causing cutaneous photosensitivity that may last for up to 6 weeks), and benzoporphyrin derivative (BPD verteporfin, causing cutaneous photosensitivity of a few days). Lin *et al.* relate to the photodynamic
25 occlusion of choroidal vessels using benzoporphyrin derivative BPD-MA. Further, BPD and tin purpurin (SnET2) are insoluble in aqueous solutions and require hydrophobic vehicles for administration.

30 Texaphyrins are aromatic pentadentate macrocyclic expanded porphyrins" useful as MRI contrast agents, as radiosensitizers and in photodynamic therapy. Texaphyrin is considered as being an aromatic benzannulene containing both 18 - and 22 -electron
35 delocalization pathways. Texaphyrin molecules absorb strongly in the tissue-transparent 700-900 nm range, and they exhibit inherent selective uptake or biolocalization in certain tissues, particularly regions such as, for example, liver,

5 atheroma or tumor tissue. Paramagnetic texaphyrins have exhibited significant tumor selectivity as detected by magnetic resonance imaging. Texaphyrins and water-soluble texaphyrins, method of preparation and various uses have been described in U.S. Patents 4,935,498; 5,162,509; 5,252,720; 5,256,399; 5,272,142; 5,292,414; 5,369,101; 5,432,171; 5,439,570; 5,451,576; 5,457,183; 5,475,104; 5,504,205; 5,525,325; 10 5,559,207; 5,565,552; 5,567,687; 5,569,759; 5,580,543; 5,583,220; 5,587,371; 5,587,463; 5,591,422; 5,594,136; 5,595,726; 5,599,923; 5,599,928; 5,601,802; 15 5,607,924; and 5,622,946; PCT publications WO 90/10633, 94/29316, 95/10307, 95/21845, and 96/09315; allowed U.S. patent applications 08/484,551 and 08/624,311; and pending U.S. patent applications 08/458,347; 08/657,947; 08/591,318; 08/700,277; 15 and 08/763,451; each patent, publication, and application is incorporated herein by reference.

Problems with prior art drug and PDT delivery systems include lack of specificity, toxicity, expense, and technical difficulties, among others. Problems with prior art magnetic resonance imaging contrast agents include insufficient differential biolocalization, insufficient signal, toxicity, and slow clearance, among others. Because of these problems, known procedures are not completely satisfactory, and the present inventors have searched for improvements.

SUMMARY OF THE INVENTION

25 The present invention relates generally to the fields of targeted drug delivery, medical imaging, diagnosis, and treatment. More particularly, it concerns compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle; and methods for imaging, diagnosis and treatment using this loaded vesicle.

Accordingly, the present invention provides compositions comprising a 30 texaphyrin-lipophilic molecule-vesicle complex. Such compositions include cells of the vascular system, such as red blood cells or white blood cells, and micellar vesicles such as liposomes or nonphospholipid vesicles, loaded with a texaphyrin conjugated to a lipophilic molecule. When the texaphyrin portion of the complex is photosensitive and when the complex is irradiated, the complex ruptures, depositing its contents. The 35 invention therefore includes methods for delivering diagnostic or therapeutic agents via loaded texaphyrin-lipophilic molecule-vesicle complexes.

5 "Loading" means labeling of membranes of a vesicle, embedding into a vesicular membrane, or incorporation into the interior of a vesicle. In particular, loading would include attachment to or within cells circulating within the vascular system or to or within liposomes or other lipid vesicles.

10 A texaphyrin-lipophilic molecule-biological vesicle complex is an embodiment of the present invention. By "biological vesicle" is meant a membranous structure having a lipid bilayer, or a micelle. By "lipid bilayer" is meant a bimolecular sheet of phospholipids and/or glycolipids. A biological vesicle may be a cell, such as a red cell or white cell, or membranous fragment thereof; a liposomal membrane; a nonphospholipid vesicle, or a colloidal drug delivery system. In one embodiment of the 15 present invention, the biological vesicle is a rescaled red blood cell.

20 As used herein, a "lipophilic molecule" is a molecule having a lipid-water distribution coefficient that is optimal for localization to lipid-rich tissues or materials compared to localization in surrounding nonlipid-rich tissues or materials. "Lipid-rich" means having a greater amount of triglyceride, cholesterol, fatty acids or the like.

25 Lipophilic molecules that may be conjugated to a texaphyrin include cholesterol; steroids including progestagens such as progesterone, glucocorticoids such as cortisol, mineralocorticoids such as aldosterone, androgens such as testosterone and androstanedione, and estrogens such as estrone and estradiol; phospholipids such as phosphatidyl choline, phosphatidyl serine, phosphatidyl ethanolamine, phosphatidyl inositol, or cardiolipin; sphingolipids such as sphingomyelin; glycolipids such as cerebroside, or ganglioside; molecules having isoprenoid side chains such as vitamin K₂, coenzyme Q₁₀, chlorophyll, or carotenoids; low density lipoprotein (LDL); or the like. Preferred lipophilic molecules are steroids, more preferably estradiol, or cholesterol, for example.

30 A method for photodynamic therapy is also an aspect of the present invention. The method comprises administering a photosensitive texaphyrin-lipophilic molecule-vesicle complex to a subject, and irradiating the complex. Preferably, the vesicle portion of the complex is a red blood cell, and in one embodiment, the subject is a donor of the red blood cell.

35 When loaded with a photosensitive texaphyrin-lipophilic molecule conjugate, a loaded vesicle has utility as a diagnostic or therapeutic agent since the cell or liposome can be disrupted using an appropriate light source, thereby depositing a diagnostic or

5 therapeutic agent *in vivo*. Therefore, a method for delivery of an agent to a targeted biological site is a further embodiment of the present invention. The method comprises i) loading a vesicle with a photosensitive texaphyrin-lipophilic molecule conjugate and the agent to form a complex; ii) allowing the complex to locate at the targeted biological site; and iii) irradiating the complex. The complex is lysed by irradiating, 10 thereby delivering the agent to the targeted biological site. The agent may be a diagnostic agent, photodynamic therapy agent, a chemotherapeutic agent, a radiation sensitizing agent, or naturally occurring cellular contents of a cell. A preferred vesicle portion of a complex to be loaded is a red blood cell, a preferred lipophilic molecule portion of a complex is estradiol or cholesterol, and the photosensitive texaphyrin- 15 lipophilic molecule conjugate may have a diamagnetic metal cation bound by the texaphyrin. A preferred diamagnetic metal cation is Lu(III), La(III), In(III), Y(III), Zn(II) or Cd(II); a most preferred diamagnetic metal cation is Lu(III). Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a therapeutic PDT agent to a desired site with a high 20 concentration of oxygen. By presenting a PDT agent this way, it is expected that the patient will experience less toxicity.

The method of photolysis of loaded blood cells or liposomes involves at least two sources of specificity. A first source of specificity is the natural localization of loaded cells or liposomes into the blood, liver, spleen, bone marrow, or lymphoid 25 organs. A second source of specificity is the positioning of the laser light. Such positioning of laser light, either by manual or mechanical means, would be particularly advantageous when the photolysis is to be effected at a particular biological locus, such as, for instance, a deep-seated tumor site. Here, the fact that the texaphyrins absorb light at wavelengths where bodily tissues are relatively transparent (700-900 nm) is 30 particularly advantageous. This procedure allows for the effective implementation of light-based strategies at loci deep within the body with relatively little deleterious light-based photosensitization of other tissues where the texaphyrin conjugates are not localized or where the light is not focused.

Further, the present invention provides for the possibility of using the patient's 35 own blood for loading with a diagnostic or a therapeutic agent and a texaphyrin-lipophilic molecule conjugate. In so doing, a uniquely "customized" therapy with reduced toxicity, increased circulation, and maximum therapeutic effect is provided.

5 Vesicles loaded with a photosensitive texaphyrin-lipophilic molecule conjugate and a chemotherapeutic drug have utility in conventional chemotherapy. In such a case, by directing laser light at a tumor and lysing the vesicle, a chemotherapeutic agent is released only in proximity to the cancer. In addition, a localized photodynamic therapeutic effect of irradiating the texaphyrin will occur.

10 Another embodiment of the present invention is a method of imaging. The method comprises the steps of administering a detectable texaphyrin-lipophilic molecule-vesicle complex to a subject, and imaging the complex.

15 When the detectable texaphyrin is fluorescent, imaging is by observing fluorescence of the texaphyrin. When the detectable texaphyrin is complexed with a paramagnetic metal cation, imaging is by magnetic resonance imaging. Further imaging methods include x-ray imaging, Raman scattering, magnetometry (bioluminescence), or gamma scanning when the texaphyrin is complexed with a gamma emitting isotope. For fluorescent imaging, texaphyrins may be activated by 400-500 nm light (the Soret band) or 700-900 nm light, preferably 700-800 nm, (the Q band) and, therefore, provide 20 considerable versatility for use in humans.

25 The term "fluorescent", as used herein, means that upon photoirradiation by light associated with the absorption profile of texaphyrin, light is emitted at a longer wavelength by the irradiated texaphyrin. All texaphyrins are fluorescent, albeit, to varying degrees, and texaphyrins complexed with Y(III), Lu(III), Gd(III), Dy(III), Eu(III), or Mn(III) are particularly preferred as fluorescent texaphyrins, for example.

30 In addition to fluorescent detection, texaphyrins may be imaged by x-radiation, by Raman scattering, or by magnetometry; further, texaphyrins complexed with a paramagnetic metal cation may be used for magnetic resonance imaging. Preferred paramagnetic metal cations for complexing with a texaphyrin include Mn(II), Mn(III), Fe(III), or trivalent lanthanide metals other than La(III), Lu(III), and Pm(III). More preferably, the paramagnetic metal is Mn(II), Mn(III), Dy(III), or Gd(III); most preferably, Gd(III). Any of various types of magnetic resonance imaging can be employed in the practice of the invention, including, for example, nuclear magnetic resonance (NMR), NMR spectroscopy, and electronic spin resonance (ESR). The 35 preferred imaging technique is NMR.

Gamma particle detection may be used to image a texaphyrin complexed to a gamma-emitting metal. ⁵¹Chromium, ⁶⁸gallium, ⁹⁹technetium, or ¹¹¹indium are

5 preferred metals for complexing to texaphyrins for gamma particle scanning.
Monochromatic X-ray photon sources may be used for imaging also.

The present invention is useful in imaging a patient generally, and/or in specifically diagnosing the presence of diseased tissue in a patient. The imaging process of the present invention may be carried out by administering a detectable 10 texaphyrin-lipophilic molecule-vesicle complex of the invention to a patient, and then scanning the patient to obtain visible images of an internal region of a patient and/or of any diseased tissue in that region. The complexes of the present invention are particularly useful in providing images of the blood pool, liver, reticuloendothelial system, spleen, bone marrow, lymph nodes, and muscle; they are especially effective 15 blood pool agents, and are highly effective at enhancing the liver and highly useful for improving the detection of hepatic metastases. Red blood cells loaded with a texaphyrin-lipophilic molecule conjugate, when injected intravenously, have been demonstrated to serve as a contrast agent for MRI. Vesicles loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, 20 facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. The patient may be any type of animal, but preferably is a mammal, and most preferably is a human.

Texaphyrin-lipophilic molecule conjugates and texaphyrin-lipophilic molecule- 25 vesicle complexes are also provided for use in ocular diagnosis and therapy, in particular, therapy involving photodynamic therapy of conditions of the eye characterized by abnormal vasculature. Accordingly, an aspect of the present invention is directed to a method for carrying out angiography of the eye, i.e., observing vasculature of an eye of a subject. The method comprises the steps of administering a 30 detectable texaphyrin-lipophilic molecule or texaphyrin-lipophilic molecule-vesicle complex to the subject; and observing the vasculature of the eye. Observing may be by fluorescence or other imaging methods as herein described.

In a further aspect of the invention, a method for treating an ocular condition of a subject characterized by abnormal vasculature is provided. The method comprises the 35 steps of administering a photosensitive texaphyrin-lipophilic molecule conjugate or a photosensitive texaphyrin-lipophilic molecule-vesicle complex to the subject; and

5 photoirradiating the vasculature. The method may further comprise the step of observing the ocular condition of the subject by imaging the texaphyrin as stated herein.

A method for photodynamic therapy of macular degeneration of a subject, comprising the steps of administering a photosensitive texaphyrin-lipophilic molecule conjugate or texaphyrin-lipophilic molecule-vesicle complex to the subject; and

10 photoirradiating the macula is another aspect of the invention.

A method for observing and treating an ocular condition of a subject characterized by abnormal vasculature using a single agent is also an aspect of the invention. The method comprises the steps of administering a photosensitive fluorescent texaphyrin-lipophilic molecule or a photosensitive fluorescent texaphyrin-15 lipophilic molecule-vesicle complex to the subject; observing the ocular condition of the subject by fluorescence of the texaphyrin; and photoirradiating the vasculature.

For angiography, texaphyrins may be activated by 400-500 nm light (the Soret band) or 700-800 nm light (the Q band) and, therefore, provide considerable versatility for use in humans. For phototherapy, texaphyrins may be irradiated at 400-500 nm and 20 at longer wavelengths of light where ocular tissues are relatively transparent, especially where light can penetrate blood and vascular tissue, i.e., 700-800 nm, especially at about 732 nm. Texaphyrins are particularly effective as visualizing agents in angiography of ocular blood vessels due to their localization in areas of abnormal permeability or damage as described in USSN 08/763,451, incorporated by reference herein.

25 Texaphyrin-lipophilic molecules or texaphyrin-lipophilic molecule-vesicle complexes can be administered in a bolus injection allowing for a sufficiently large amount of drug to be present in the blood and for fast-turnaround between dosing and treatment. Further, texaphyrins are cleared quickly from the body; no toxicity to the eye has been observed in the use of texaphyrins in angiography.

30 A method of inducing formation of antibodies having binding specificity for a texaphyrin in a subject is also an aspect of the present invention. This method comprises administering a photosensitive texaphyrin-lipophilic molecule-vesicle complex to a subject, and irradiating the complex. Irradiating with light disrupts the vesicle, causing the contents to be deposited in the subject, thereby exposing the subject to the texaphyrin and inducing antibody production to texaphyrin. In this case, the texaphyrin may be considered a hapten; if the vesicle is a foreign cell, then the vesicle 35 may be considered an adjuvant in addition to being the carrier that delivers the

5 texaphyrin. By "foreign" is meant that the loaded vesicle is from a different species of animal than the animal into which the loaded cell is administered. For example, the cell for loading may be a goat cell, and the subject administered the loaded cell may be a rabbit.

10 In addition, a further immunogen may be loaded into the vesicle for inducing antibodies having binding specificity for that immunogen. Antibodies having binding specificity for the cellular contents of the disrupted cell may also be formed.

15 A further aspect of the invention is an antibody having binding specificity for a texaphyrin molecule. Such antibodies are useful for purification of a texaphyrin, for screening assays for the presence of a texaphyrin, or for the presence of texaphyrin degradation products from metabolic processes.

20 A method of making a texaphyrin-lipophilic molecule-cell complex is an aspect of the present invention. The method comprises i) obtaining a texaphyrin-lipophilic molecule conjugate, and ii) incubating a cell with the texaphyrin-lipophilic molecule conjugate in a hypotonic saline solution for a time and under conditions wherein a texaphyrin-lipophilic molecule-cell complex is formed. An optional step is to include a drug or therapeutic agent when incubating in the hypotonic solution. A preferred cell is an erythrocyte. Advantages of using resealed or modified autologous erythrocytes as drug carriers include the fact that they are biodegradable, fully biocompatible, and nonimmunogenic; they exhibit flexibility in circulation time depending on their 25 physicochemical properties; the entrapped drug is shielded from immunologic detection; and chemical modification of a drug is not required.

30 A method of making a texaphyrin-lipophilic molecule-liposome complex is an aspect of the present invention. The method comprises the step of incubating a texaphyrin-lipophilic molecule conjugate with a lipid or incorporating a texaphyrin-lipophilic molecule into a preformed liposome or micelle for a time and under conditions wherein a texaphyrin-lipophilic molecule-liposome complex is formed. An optional step is to include a drug or therapeutic agent during the incubation or incorporation.

35 In summary, a vesicle loaded with a texaphyrin-lipophilic molecule conjugate is useful in medical imaging, diagnosis, and therapy.

Following long-standing patent law convention, the terms "a" and "an" mean "one or more" when used in this application, including the claims.

5 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Loading of a biological vesicle, such as a red blood cell (RBC), white blood cell (WBC), or a liposome with a texaphyrin-lipophilic molecule conjugate has previously not been shown. In the present invention, RBC's were successfully loaded with GdT2BET-estradiol conjugate (GTE 1A). However, attempted loading with GdT2BET alone was not successful, thereby indicating that a lipophilic molecule "handle" is an important aspect of the texaphyrin conjugate for loading success. Although the examples that follow demonstrate loading of red blood cells, the invention is not limited thereto; it is contemplated that other cells may be loaded as well, such as stem cells, bone marrow cells, platelets, granulocytes, lymphocytes including T and B cells, monocytes, neutrophils, eosinophils, plasma cells, macrophage, dendritic cells, or a cell of mesenchymal, ectodermal, or endodermal origin. Macrophages loaded with a texaphyrin-lipophilic molecule conjugate are expected to have utility in the treatment of atheroma since macrophages complex with cholesterol to form foam cells, a component of early atheroma.

Loaded vesicles will naturally biolocalize into the blood, liver, spleen, bone marrow or lymphoid organs. Due to the size of a vesicle, such as a red blood cell or a liposome, compared to the size of a texaphyrin-lipophilic molecule conjugate, it is expected that the vesicle will dominate in terms of biolocalization, and any localizing effect of a site-directing lipophilic molecule or the inherent biolocalization of texaphyrins will be secondary. For example, a texaphyrin-estradiol conjugate loaded into a vesicle may have some specificity for an estradiol receptor if the estradiol is superficial to the vesicle. Similarly, a vesicle loaded with a texaphyrin-cholesterol conjugate may have localization to the liver in addition to the natural localization of the vesicle to the liver.

Human LDL is a physiologic serum protein metabolized by cells via uptake by high affinity receptors. In particular, neovascularization has been shown to have increased numbers of LDL receptors; and by increasing the partitioning of the texaphyrin into the lipoprotein phase of the blood, LDL is expected to more efficiently deliver texaphyrin to target tissue. A texaphyrin-LDL conjugate is selective for neovascularization since leakage of the conjugate is expected to occur only in neovasculation due to the large size of the conjugate. LDL can be isolated and purified according to the procedure of Hauel *et al.*, (*J. Clin. Invest.*, 34:1345, 1995).

5 In the loading of red blood cells of the present invention, red blood cells are separated from plasma and washed in normal saline. They are then treated with hypertonic saline which leaves them crenated with their internal salt concentration being higher than normal. The crenated cell pellet is resuspended in hypotonic saline containing a texaphyrin-lipophilic molecule conjugate. Because of the concentration
10 difference between the cell interior and the hypotonic solution, water and the conjugate are driven into the cells. The cells are then washed several times in normal saline. This procedure results in a red blood cell with extensive labeling with the texaphyrin-lipophilic molecule conjugate. Further methods for loading cells are known to those of skill in this art in light of the present disclosure and may be utilized in the preparation of
15 complexes of the present invention, for example, inducing an osmotic difference by use of sucrose solutions, treating with calcium chloride or calcium phosphate, or the like.

20 White cells are obtained from blood by, for example, centrifugation through Ficoll Hypaque media. This separates the white blood cells from plasma components and red blood cells. Other techniques for obtaining specific types of cells are known to one of skill in the art in light of the present disclosure.


25 Liposomes may be prepared by any number of techniques that include freeze-thaw, sonication, chelate dialysis, homogenization, solvent infusion, microemulsification, spontaneous formation, solvent vaporization, reverse phase, French pressure cell technique, or controlled detergent dialysis, for example. Such preparation methods are known to one of skill in the art in light of the present disclosure. Preparation may be carried out in a solution, such as a phosphate buffer solution, containing a texaphyrin-lipophilic molecule conjugate so that the conjugate is incorporated into the liposome membrane. Alternatively, the conjugate may be added to already formed liposomes. Liposomes employed in the present invention may be of any
30 30 one of a variety of sizes, preferably less than about 100 nm in outside diameter, more preferably less than about 50 nm.

35 Micelles may be prepared by suspension of a texaphyrin-lipophilic molecule and lipid compound(s) in an organic solvent, evaporation of the solvent, resuspension in an aqueous medium, sonication and then centrifugation. Alternatively, the texaphyrin-lipophilic molecule may be added to preformed micelles, which micelles are made by methods known by one of skill in the art in light of the present disclosure.

5 Techniques and lipids for preparing liposomes and micelles are discussed in U.S. Patent 5,466,438, and references cited therein. The disclosures of each of the foregoing references are incorporated herein by reference.

10 A texaphyrin-lipophilic molecule conjugate as used herein is an aromatic pentadentate expanded porphyrin analog with appended functional groups, at least one of which is a lipophilic molecule. Pendant groups may enhance solubility or biolocalization or may provide coupling sites for site-directing molecules.

Examples of texaphyrin-lipophilic molecule conjugates are those having structure I or structure II:




5

10

15

20



II

25 **M** is H, or a divalent or trivalent metal cation. A preferred divalent metal cation is Ca(II), Mn(II), Co(II), Ni(II), Zn(II), Cd(II), Hg(II), Fe(II), Sm(II), or UO₂(II). A preferred trivalent metal cation is Mn(III), Co(III), Ni(III), Fe(III), Ho(III), Ce(III),

30 Y(III), In(III), Pr(III), Nd(III), Sm(III), Eu(III), Gd(III), Tb(III), Dy(III), Er(III), Tm(III), Yb(III), Lu(III), La(III), or U(III). Most preferred trivalent metal cations are Lu(III) and Gd(III).

R₁-**R**₄, **R**₇ and **R**₈ are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, a lipophilic molecule, or a couple that is coupled to a lipophilic molecule.

35 **R**₆ and **R**₉ are independently selected from the groups of **R**₁-**R**₄, **R**₇ and **R**₈, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl.

R₅ and **R**₁₀-**R**₁₂ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, or a couple that is coupled to a saccharide, or to a lipophilic molecule. The term "n" is an integer value less than or equal to 5.

40 **R**₁₃ is alkyl, alkenyl, oxyalkyl, or hydroxyalkyl having up to about 3 carbon atoms and having rotational flexibility around a first-bound carbon atom. Rotational flexibility allows the rest of the group to be positioned outside the plane of the texaphyrin. Thus, for example, a preferred alkenyl is CH₂-CH=CH₂. The pyrrole

5 nitrogen substituent is most preferably a methyl group. A texaphyrin having a methyl group attached to a ring nitrogen is described in U.S. Patent 5,457,183, incorporated by reference herein.

In this texaphyrin-lipophilic molecule conjugate, at least one of R_1-R_{12} is a lipophilic molecule or a couple that is coupled to a lipophilic molecule. In a more 10 preferred embodiment, at least one of R_1, R_2, R_3, R_4, R_7 and R_8 is a lipophilic molecule, and more preferably is estradiol or cholesterol, or a couple that is coupled to estradiol or cholesterol. In a presently preferred embodiment, the texaphyrin-lipophilic molecule conjugate is the conjugate depicted herein as **1A** or **1B**.

15 Texaphyrins of the present conjugates may be metal-free or may be in a complex with a metal. Divalent and trivalent metal complexes of texaphyrins are by convention shown with a formal charge of n^+ , where $n=1$ or 2, respectively. The value "n" will typically be an integer less than or equal to 5; however, one skilled in the art in light of the present disclosure would realize that the value of n would be altered due to any charges present on substituents R_1-R_{12} .

20 It is understood by those skilled in the art that texaphyrin-metal complexes have one or more additional ligands providing charge neutralization and/or coordinative saturation to the metal ion. Such ligands include chloride, nitrate, acetate, cholate, and hydroxide, among others.

25 Photosensitive texaphyrins are used for PDT. A photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. The term "photosensitive," as used herein, means that upon photoirradiation by light associated with the absorption profile of texaphyrin, texaphyrin effects the generation of oxygen products that are cytotoxic. Cytotoxic oxygen products may be singlet oxygen, hydroxyl radicals, superoxide, hydroperoxyl radicals, or the like. A photosensitive 30 texaphyrin may be a texaphyrin metal complex, and in this embodiment, the metal M is a diamagnetic metal cation and the diamagnetic metal cation preferably is Lu(III), La(III), In(III), Y(III), Zn(II) or Cd(II). A more preferred diamagnetic metal cation is Lu(III).

35 Representative examples of alkanes useful as alkyl group substituents of the present invention include methane, ethane, straight-chain, branched or cyclic isomers of propane, butane, pentane, hexane, heptane, octane, nonane and decane, with methane, ethane and propane being preferred. Alkyl groups having up to about thirty, or up to about

5 fifty carbon atoms are contemplated in the present invention. Representative examples of substituted alkyls include alkyls substituted by two or more functional groups as described herein.

10 Representative examples of alkenes useful as alkenyl group substituents include ethene, straight-chain, branched or cyclic isomers of propene, butene, pentene, hexene, heptene, octene, nonene and decene, with ethene and propene being preferred. Alkenyl groups having up to about thirty or fifty carbon atoms, and up to about five double bonds, or more preferably, up to about three double bonds are contemplated in the present invention.

15 Representative examples of alkynes useful as alkynyl group substituents include ethyne, straight-chain, branched or cyclic isomers of propyne, butyne, pentyne, hexyne, heptyne, octyne, nonyne and decyne, with ethyne and propyne being preferred. Alkynyl groups having up to about thirty, or up to about fifty carbon atoms, and having up to about five or up to about three triple bonds are contemplated in the present invention.

20 The aryl may be a compound whose molecules have the ring structure characteristic of benzene, naphthalene, phenanthrene, anthracene, and the like, i.e., either the 6-carbon ring of benzene or the condensed 6-carbon rings of the other aromatic derivatives. For example, an aryl group may be phenyl or naphthyl, and the term as used herein includes both unsubstituted aryls and aryls substituted with one or more nitro, carboxy, sulfonic acid, hydroxy, oxyalkyl or halide substituents. In this case, the 25 substituent on the phenyl or naphthyl may be added in a synthetic step after the condensation step which forms the macrocycle.

30 Among the halide substituents, chloride, bromide, fluoride and iodide are contemplated in the practice of this invention with the exception of iodide for R_6 and R_9 . R_6 and R_9 may have chloride, bromide or fluoride substituents. Representative examples of haloalkyls used in this invention include halides of methane, ethane, propane, butane, pentane, hexane, heptane, octane, nonane and decane, with halides, preferably chlorides or bromides, of methane, ethane and propane being preferred.

35 "Hydroxyalkyl" means alcohols of alkyl groups. Preferred are hydroxyalkyl groups having one to twenty, more preferably one to ten, hydroxyls. "Hydroxyalkyl" is meant to include glycols and polyglycols; diols of alkyls, with diols of C_{1-10} alkyls being preferred, and diols of C_{1-3} alkyls being more preferred; and polyethylene glycol,

5 polypropylene glycol and polybutylene glycol as well as polyalkylene glycols containing combinations of ethylene, propylene and butylene.

Representative examples of oxyalkyls include the alkyl groups as herein described having ether linkages. "Oxyalkyl" is meant to include polyethers with one or more functional groups. The number of repeating oxyalkyls within a substituent may be up to 10 200, preferably is from 1-20, and more preferably, is 1-10, and most preferably is 1-5. A preferred oxyalkyl is $O(CH_2CH_2O)_xCH_3$ where $x = 1-100$, preferably 1-10, and more preferably, 1-5.

15 "Oxyhydroxyalkyl" means alkyl groups having ether or ester linkages, hydroxyl groups, substituted hydroxyl groups, carboxyl groups, substituted carboxyl groups or the like.

20 Representative examples of thioalkyls include thiols of ethane, thiols of straight-chain, branched or cyclic isomers of propane, butane, pentane, hexane, heptane, octane, nonane and decane, with thiols of ethane (ethanethiol, C_2H_5SH) or propane (propanethiol, C_3H_7SH) being preferred. Sulfate-substituted alkyls include alkyls as described above 25 substituted by one or more sulfate groups, a representative example of which is diethyl sulfate ($(C_2H_5)_2SO_4$).

Representative examples of phosphates include phosphate or polyphosphate groups. Representative examples of phosphate-substituted alkyls include alkyls as described above substituted by one or more phosphate or polyphosphate groups.

25 Representative examples of phosphonate-substituted alkyls include alkyls as described above substituted by one or more phosphonate groups.


Representative examples of carboxy groups include carboxylic acids of the alkyls described above as well as aryl carboxylic acids such as benzoic acid. Representative examples of carboxyamides include primary carboxyamides ($CONH_2$), secondary 30 ($CONHR'$) and tertiary ($CONRR''$) carboxyamides where each of R' and R'' is a functional group as described herein.

Representative examples of useful amines include a primary, secondary or tertiary amine of an alkyl as described hereinabove.

35 "Carboxyamidealkyl" means alkyl groups with secondary or tertiary amide linkages or the like. "Carboxyalkyl" means alkyl groups having hydroxyl groups, carboxyl or amide substituted ethers, ester linkages, tertiary amide linkages removed from the ether or the like.

5 The term "saccharide" includes oxidized, reduced or substituted saccharide; hexoses such as D-glucose, D-mannose or D-galactose; pentoses such as D-ribose or D-arabinose; ketoses such as D-ribulose or D-fructose; disaccharides such as sucrose, lactose, or maltose; derivatives such as acetals, amines, and phosphorylated sugars; oligosaccharides, as well as open chain forms of various sugars, and the like. Examples of
10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110

5 Presently preferred texaphyrin-lipophilic molecule conjugates, T2BET-estradiol
 conjugates, are provided as 1_A and 1_B .



"T2" refers to two hydroxyl groups on the tripyrrane portion of texaphyrin,
 "BET" refers to the ethoxy R groups on the benzene portion of the molecule, and
 25 estradiol is the lipophilic molecule of this conjugate. The synthesis of this conjugate is
 provided in Example 1.

In other presently preferred texaphyrin compounds I or II, R_1-R_{12} are as in Tables
 A and B for texaphyrins A1-A108, and M is as defined hereinabove. While the cited
 texaphyrins are presently preferred for use in the present invention, the invention is not
 30 limited thereto.

TABLE A
Representative Substituents for Texaphyrin Macrocycles A1-A108 of the Present Invention.
Substituents for R₁-R₆ are provided in TABLE A and for R₇-R₁₂ in TABLE B.

TXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A1	CH ₂ (CH ₂) ₂ OH	CH ₂ CH ₃	CH ₂ CH ₃	CH ₃	H	H
A2	"	"	"	"	"	"
A3	"	"	"	"	"	"
A4	"	"	"	"	"	"
A5	"	"	"	"	"	"
A6	"	"	"	"	"	"
A7	"	"	"	"	"	"
A8	"	"	"	"	"	"
A9	"	"	"	"	"	"
A10	"	"	"	"	"	"
A11	"	"	"	"	"	"
A12	"	COOH	COOH	"	"	"
A13	CH ₂ (CH ₂) ₂ OH	COOCH ₂ CH ₃	COOCH ₂ CH ₃	CH ₃	H	H
A14	CH ₂ CH ₂ CON(CH ₂ CH ₂ OH) ₂	CH ₂ CH ₃	CH ₂ CH ₃	"	"	"

TABLE A - CONTINUED

TXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A15	CH ₂ CH ₂ ON(CH ₃)CH ₂ (CH ₂ OH) ₄ CH ₂ OH	"	"	"	"	"
A16	CH ₂ CH ₃	"	"	"	"	"
A17	CH ₂ (CH ₂) ₂ OH	"	"	"	"	"
A18	"	"	"	"	"	"
A19	"	"	"	"	"	"
A20	CH ₃ CH ₃	CH ₃	CH ₃ CH ₂ COOH	"	"	"
A21	"	"	CH ₃ CH ₂ CO-	"	"	"
			lipophilic molecule			
A22	CH ₂ (CH ₂) ₂ OH	CH ₂ CH ₃	CH ₂ CH ₃	"	"	"
A23	"	"	"	"	"	"
A24	"	"	"	"	"	"
A25	"	"	"	"	"	"
A26	"	"	"	"	"	"
A27	"	COOH	COOH	"	"	"
A28	"	COOCH ₂ CH ₃	COOCH ₂ CH ₃	"	"	"

TABLE A - CONTINUED

EXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A29	CH ₂ CH ₂ CO-lipophilic molecule	CH ₂ CH ₃	CH ₂ CH ₃	CH ₃	H	H
A30	CH ₂ CH ₂ O-lipophilic molecule	"	"	"	"	"
A31	CH ₂ (CH ₂) ₂ OH	"	CH ₂ CH ₂ CO-lipophilic molecule	"	"	"
A32	"	"	"	"	"	"
A33	CH ₂ CH ₃	CH ₃	CH ₂ CH ₂ COOH	"	"	"
A34	"	"	CH ₂ CH ₂ CO-lipophilic molecule	"	"	"
A35	CH ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	"	"	"
A36	"	"	"	"	"	"
A37	"	"	"	"	"	"
A38	"	"	"	"	"	"
A39	CH ₂ (CH ₂) ₂ OH	CH ₂ CH ₃	CH ₂ CH ₃	CH ₃	H	COOH
A40	"	"	"	"	"	COOH
A41	"	"	"	"	"	CONHCH-(CH ₂ OH) ₂

TABLE A - CONTINUED

TXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A42	"	"	"	"	"	"
A43	"	"	"	"	"	H
A44	"	"	"	"	"	OCH ₃
A45	"	"	"	"	"	"
A46	"	"	"	"	"	"
A47	"	"	"	"	"	"
A48	"	"	"	"	"	"
A49	"	"	"	"	"	"
A50	"	"	"	"	"	CH ₃
A51	"	"	"	"	"	"
A52	"	"	"	"	"	"
A53	"	"	"	"	"	"
A54	"	"	"	"	CH ₃	H
A55	"	"	"	"	"	"
A56	"	"	"	"	"	"
A57	CH ₂ (CH ₂) ₂ OH	CH ₂ CH ₃	CH ₂ CH ₃	CH ₃	CH ₃	H

TABLE A - CONTINUED

TXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A58	"	"	"	"	"	"
A59	"	"	"	"	"	"
A60	"	"	"	"	"	"
A61	"	"	"	"	"	"
A62	"	"	"	"	"	"
A63	"	"	"	"	"	OH
A64	"	"	"	"	"	F
A65	"	"	"	"	CH ₂ (CH ₂) ₆ OH	H
A66	"	"	"	"	H	Br
A67	"	"	"	"	"	NO ₂
A68	"	"	"	"	"	COOH
A69	"	"	"	"	"	CH ₃
A70	"	"	"	"	C ₆ H ₅	H
A71	"	COOH	COOH	"	CH ₂ CH ₃	"
A72	"	COOCH ₂ CH ₃	COOCH ₂ CH ₃	"	CH ₃	"
A73	CH ₂ CH ₂ CON(CH ₂ CH ₂ OH) ₂	CH ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	"	"

TABLE A - CONTINUED

TXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A74	CH ₂ CH ₂ ON(CH ₃)CH ₂ (CHOH) ₂ CH ₂ OH	"	"	"	"	"
A75	CH ₃ CH ₃	"	"	"	"	"
A76	CH ₃ (CH ₂) ₂ OH	CH ₃ CH ₃	CH ₃ CH ₃	CH ₃	CH ₃ or CH ₂ CH ₃	H
A77	"	"	"	"	"	"
A78	"	"	"	"	"	"
A79	"	"	"	"	"	"
A80	"	"	"	"	"	"
A81	"	"	"	"	"	"
A82	"	"	"	"	"	"
A83	"	"	"	"	"	"
A84	"	"	"	"	"	"
A85	"	"	"	"	H	"
A86	"	"	"	"	"	"
A87	"	"	"	"	CH ₃ or CH ₂ CH ₃	"
A88	"	"	"	"	"	"

TABLE A - CONTINUED

TXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A89	"	"	"	"	H	H
A90	"	"	"	"	"	"
A91	"	"	"	"	"	"
A92	"	"	"	"	"	"
A93	"	COOH	COOH	"	"	"
A94	"	COOCH ₂ CH ₃	COOCH ₂ CH ₃	"	"	"
A95	CH ₂ (CH ₂) ₂ OH	CH ₃ CH ₃	CH ₃ CH ₂ CO- lipophilic molecule	"	"	"
A96	CH ₂ CH ₃	CH ₃	CH ₃ CH ₂ COOH	"	"	"
A97	"	"	CH ₃ CH ₂ CO- lipophilic molecule	"	"	"
A98	CH ₃ (CH ₂) ₂ OH	CH ₃ CH ₃	CH ₃ CH ₃	"	"	"
A99	CH ₂ CH ₃	"	"	"	"	"
A100	"	"	"	"	"	"
A101	"	"	"	"	"	"
A102	"	"	"	"	"	"

TABLE A - CONTINUED

TXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A89	"	"	"	"	H	H
A90	"	"	"	"	"	"
A91	"	"	"	"	"	"
A92	"	"	"	"	"	"
A93	"	COOH	COOH	"	"	"
A94	"	COOCH ₂ CH ₃	COOCH ₂ CH ₃	"	"	"
A95	CH ₂ (CH ₂) ₂ OH	CH ₂ CH ₃	CH ₂ CH ₂ CO- lipophilic molecule	"	"	"
A96	CH ₂ CH ₃	CH ₃	CH ₂ CH ₂ COOH	"	"	"
A97	"	"	CH ₂ CH ₂ CO- lipophilic molecule	"	"	"
A98	CH ₂ (CH ₂) ₂ OH	CH ₂ CH ₃	CH ₂ CH ₃	"	"	"
A99	CH ₂ CH ₃	"	"	"	"	"
A100	"	"	"	"	"	"
A101	"	"	"	"	"	"
A102	"	"	"	"	"	"

TABLE A - CONTINUED

TXP	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
A103	"	"	"	"	"	"
A104	"	"	"	"	"	"
A105	CH ₂ (CH ₂) ₂ OH	"	"	"	"	"
A106	"	"	"	"	"	"
A107	"	"	"	"	"	"
A108	"	"	"	"	"	"

TABLE B
 Representative Substituents for Texaphyrin Macrocycles A1-A108 of the Present Invention.
 Substituents for R₁-R₆ are provided in TABLE A and for R₇-R₁₂ in TABLE B.

TXP	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂
A1	O(CH ₂) ₃ OH	O(CH ₂) ₃ OH	H	H	H	H
A2	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A3	O(CH ₂) _n CON-linker-lipophilic molecule, n=1-10	"	"	"	"	"
A4	O(CH ₂) _n CON-linker-lipophilic molecule, n=1-10	H	"	"	"	"
A5	OCH ₂ CO-lipophilic molecule	"	"	"	"	"
A6	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"	"
A7	OCH ₂ CON-linker-lipophilic molecule	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A8	OCH ₂ CO-lipophilic molecule	"	"	"	"	"
A9	O(CH ₂ CH ₂ O) ₁₀ CH ₃	"	"	"	"	"
A10	OCH ₂ CON(CH ₂ CH ₂ OH) ₂	H	"	"	"	"
A11	CH ₂ CON(CH ₂) ₂ CH ₂ (CHOH) ₂ CH ₂ OH	"	"	"	"	"
A12	"	"	"	"	"	"

TABLE B - CONTINUED

TRP	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂
A13	CH ₂ CON(CH ₃)CH ₂ (CHOH)CH ₂ OH	H	H	H	H	H
A14	"	"	"	"	"	"
A15	OCH ₃	OCH ₃	"	"	"	"
A16	OCH ₂ CO ₂ -lipophilic molecule	H	"	"	"	"
A17	O(CH ₂) _n COOH, n=1-10	"	"	"	"	"
A18	(CH ₂) _n -CON-linker-lipophilic molecule, n=1-10	"	"	"	"	"
A19	YCOCH ₂ -linker-lipophilic molecule, Y=NH ₂ O	"	"	"	"	"
A20	O(CH ₂) _n CH ₂ OH	O(CH ₂) _n CH ₂ OH	"	"	"	"
A21	"	"	"	"	"	"
A22	OCH ₂ COOH	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A23	O(CH ₂) _n CO-lipophilic molecule, n=1-10	H	"	"	"	"
A24	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) _n lipophilic molecule, n=1-10, in particular, n=3 or 5	"	"	"	"
A25	OCH ₃	OCH ₂ CO-lipophilic molecule	"	"	"	"
A26	"	CH ₂ CO-lipophilic molecule	"	"	"	"

TABLE B - CONTINUED

TP	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂
A27	"	"	"	"	"	"
A28	OCH ₃	CH ₃ CO-lipophilic molecule	H	H	H	H
A29	"	OCH ₃	"	"	"	"
A30	"	"	"	"	"	"
A31	H	O(CH ₂) _n COOH, n=1-10	"	"	"	"
A32	"	(CH ₂) _n -CON-linker-lipophilic molecule, n=1-10	"	"	"	"
A33	OCH ₃	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A34	"	"	"	"	"	"
A35	H	O(CH ₂) _n CO-lipophilic molecule, n=1-10	"	"	"	"
A36	OCH ₃	"	"	"	"	"
A37	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"	"
A38	"	O(CH ₂ CH ₂ O) _n -lipophilic molecule, n=1-10	"	"	"	"
A39	O(CH ₂) ₃ OH	O(CH ₂) ₃ OH	H	H	H	H
A40	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₃ CH ₃	COOH	"	"	"
A41	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₃ CH ₃	(CH ₃) ₃ OH	"	"	"
A42	"	"	O(CH ₂ CH ₂ O) ₃ C	"	"	"

TABLE B - CONTINUED

TP	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂
A43	"	O(CH ₂) ₃ COOH	"	H ₃	"	"
A44	H	OCH ₂ COOH	OCH ₃	"	"	"
A45	"	OCH ₂ COOH	"	"	"	"
A46	"	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A47	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"	"
A48	"	OCH ₂ CO-lipophilic molecule	"	"	"	"
A49	"	OCH ₂ COOH	"	"	"	"
A50	"	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₃ C H ₃	"	"	"
A51	"	OCH ₂ COOH	"	"	"	"
A52	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₁₀ CH ₃	OCH ₃	"	"	"
A53	H	OCH ₂ CO-lipophilic molecule	"	"	"	"
A54	O(CH ₂) ₃ OH	O(CH ₂) ₃ OH	H	CH ₃	"	"
A55	H	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A56	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"	"
A57	H	OCH ₂ CO-lipophilic molecule	H	CH ₃	"	"

TABLE B - CONTINUED

TXP	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂
A58	"	OCH ₂ CO-lipophilic molecule	"	"	"	"
A59	"	OCH ₂ CON(CH ₂ CH ₂ OH) ₂	"	"	"	"
A60	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A61	"	OCH ₂ CO-lipophilic molecule	"	"	"	"
A62	H	CH ₂ CON(CH ₃)CH ₂ (CHOH) ₄ CH ₂ OH	"	"	"	"
A63	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₃ CH ₃	OH	"	"	"
A64	"	"	F	"	"	"
A65	"	"	H	CH ₂ (CH ₃) ₃ OH	"	"
A66	"	"	Br	H	"	"
A67	"	"	NO ₂	"	"	"
A68	"	"	COOH	"	"	"
A69	"	"	CH ₃	"	"	"
A70	"	"	H	C ₆ H ₅	"	"
A71	"	"	"	CH ₂ CH ₃	"	"
A72	"	"	"	CH ₃	"	"

TABLE B - CONTINUED

TP	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂
A73	"	"	"	"	"	"
A74	OCH ₃	OCH ₃	"	"	"	"
A75	H	OCH ₂ CO-lipophilic molecule	"	CH ₂ (CH ₂) ₆ OH	"	"
A76	O(CH ₂) ₃ OH	O(CH ₂) ₃ OH	H	CH ₃ or CH ₂ CH ₃	CH ₃ or CH ₂ CH ₃	CH ₃ or CH ₂ CH ₃
A77	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A78	O(CH ₂) ₃ OH	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A79	H	O(CH ₂) _n CO-lipophilic molecule, n=1,2,3	"	"	"	"
A80	H	O(CH ₂) _n CO-lipophilic molecule, n=1,2,3	"	"	"	"
A81	H	O(CH ₂) ₃ OH	"	"	"	"
A82	O(CH ₂) ₃ OH	O(CH ₂) _n CO-lipophilic molecule, n=1,2,3	"	"	"	"
A83	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂) _n CO-lipophilic molecule, n=1-10	"	"	"	"
A84	"	O(CH ₂) _n CO-lipophilic molecule, n=1,2,3	"	"	"	"
A85	"	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A86	"	"	"	CH ₂ (CH ₂) ₂	CH ₂ (CH ₂) ₂	CH ₂ (CH ₂) ₂

TABLE B - CONTINUED

TKP	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂
A87	"	"	"	"	CH ₃ or CH ₂ CH ₃	"
A88	"	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"
A89	O(CH ₂ CH ₂ O) ₃ CH ₂ -CH ₂ - lipophilic molecule	O(CH ₂ CH ₂ O) ₂₀ CH ₃	H	H	H	H
A90	H	lipophilic molecule	"	"	"	"
A91	OCH ₂ CO-lipophilic molecule	OCH ₂ CO-lipophilic molecule	"	"	"	"
A92	CH ₂ CO-lipophilic molecule	CH ₂ CO-lipophilic molecule	"	"	"	"
A93	"	"	"	"	"	"
A94	"	"	"	"	"	"
A95	H	YCOCH ₂ -linker-lipophilic molecule Y=NH ₂ O	"	"	"	"
A96	O(CH ₂ CH ₂ O) ₃ CH ₃	O(CH ₂ CH ₂ O) ₃ -lipophilic molecule	"	"	"	"
A97	"	"	"	"	"	"
A98	H	O(CH ₂) ₃ CO-lipophilic molecule	"	"	"	"
A99	"	"	"	"	"	"

TABLE B - CONTINUED

TXP	R ₇	R ₈	R ₉	R ₁₀	R ₁₁	R ₁₂
A100	OCH ₃	"	"	"	"	"
A101	O(CH ₂ CH ₂ O) ₃ CH ₃	"	"	"	"	"
A102	"	O(CH ₂ CH ₂ O) ₃ -estradiol	"	"	"	"
A103	"	O(CH ₂ CH ₂ O) _n -estradiol, n=1-10	"	"	"	"
A104	"	O(CH ₂ CH ₂ O) _n -cholesterol, n=1-10	"	"	"	"
A105	"	"	"	"	"	"
A106	OCH ₃	O(CH ₂ CH ₂ O) _n -estradiol, n=1-10	"	"	"	"
A107	H	"	"	"	"	"
A108	O(CH ₂ CH ₂ O) _x CH ₃ , x = 1-10	"	"	"	"	"

One skilled in the art of organic synthesis in light of the present disclosure and the disclosures in the patents, applications and publications incorporated by reference herein could extend and refine the referenced basic synthetic chemistry to produce texaphyrins having various substituents. For example, polyether-linked polyhydroxylated groups, 5 saccharide substitutions in which the saccharide is appended via an acetal-like glycosidic linkage, an oligosaccharide or a polysaccharide may be similarly linked to a texaphyrin. A doubly carboxylated texaphyrin in which the carboxyl groups are linked to the texaphyrin core via aryl ethers or functionalized alkyl substituents could be converted to various esterified products wherein the ester linkages serve to append further hydroxyl-containing 10 substituents. Polyhydroxylated texaphyrin derivatives may be synthesized via the use of secondary amide linkages. Saccharide moieties may be appended via amide bonds. Polyhydroxylated texaphyrin derivatives containing branched polyhydroxyl (polyol) subunits may be appended to the texaphyrin core via aryl ethers or ester linkages.

15 Treatment of carboxylated texaphyrins with thionyl chloride or *p*-nitrophenol acetate would generate activated acyl species suitable for attachment to monoclonal antibodies or other biomolecules of interest. Standard *in situ* coupling methods (e.g., 1,1'-carbonyldiimidazole) could be used to effect the conjugation.

20 Substituents at the R₆ and R₉ positions on the B (benzene ring) portion of the macrocycle are incorporated into the macrocycle by their attachment to *ortho*-phenylenediamine in the 3 and 6 positions of the molecule. Substituents at the R₅ and R₁₀ positions on the T (trypyrrane) portion of the macrocycle are incorporated by appropriate functionalization of carboxyl groups in the 5 positions of the tripyrrane at a 25 synthetic step prior to condensation with a substituted *ortho*-phenylenediamine. A lipophilic molecule may be added after the condensation step to form the texaphyrin macrocycle.

30 Lipophilic molecules having an amine functionality are modified post-synthetically with an activated carboxylic ester derivative of a texaphyrin. In the presence of a Lewis acid such as FeBr₃, a bromide-derivatized texaphyrin will react with an hydroxyl group of a lipophilic molecule to form an ether linkage between the texaphyrin linker and the lipophilic molecule. A couple that is coupled to a lipophilic molecule may be further described as O(CH₂CH₂O)_m- where m is 1-10 and preferably 1-5, or as O(CH₂)_nCO- where n is 1-10 and preferably 1-3.

Texaphyrin-lipophilic molecule conjugates may be made by methods as described herein and as known and described in the art, such as in U.S. Patents, in pending applications, previously incorporated by reference herein. Texaphyrins have a number of properties that lend themselves for use in imaging and photodynamic 5 treatment protocols, for example: texaphyrins have inherent biolocalization, localizing to tumors, atheroma, or the liver; they have absorption in the physiologically important range of 700-900 nm; they provide stable chelation for an otherwise toxic metallic cation; and are sufficiently nontoxic for *in vivo* use.

An aspect of the present invention is use of texaphyrin-lipophilic molecules or 10 texaphyrin-lipophilic molecule-vesicle complexes in ocular diagnosis and therapy; especially diagnostic angiograms, and photodynamic therapy of conditions of the eye characterized by abnormal vasculature. "Abnormal vasculature", as used herein, means undesirable vasculature; neovasculature; irregular, occluded, weeping, or inflamed ocular vessels or ocular tissues; inflammatory ocular membranes; abnormal conditions 15 having to do with channeling of fluids in the ocular area, especially blood vessels; and includes conditions such as macular degeneration, glaucoma, disc or retinal neovascularization in diabetic retinopathy, pannus which is abnormal superficial vascularization of the cornea or conjunctiva, pterygium which is thickening of the bulbar conjunctiva on the cornea, conditions having retinal or choroidal neovasculature, 20 ocular histoplasmosis syndrome, myopia, ocular inflammatory diseases, central serous retinopathy, subretinal neovascular membrane, or neovasculature induced by neoplasm, such as melanoma or retinal blastoma, for example.

"Observing the vasculature", as used herein, means carrying out an imaging 25 procedure and collecting information from an angiogram where fluorescent texaphyrins are used, from an x-ray, or from magnetic resonance image, for example, to interpret the condition of the eye. The condition of the eye may be normal, or may include vascular leakage or occlusions, for example. As used herein, "eye" or "ocular" includes the eye, underlying and adjacent tissue, and related tissues near and around the eye that have an influence on the functioning of the eye.

30 The parameters used for effective angiography and effective treatment in PDT methods of the invention are interrelated. Therefore, the dose is adjusted with respect to other parameters, for example, fluence, irradiance, duration of the light used in

photodynamic therapy, and the time interval between administration of the dose and the therapeutic irradiation. Such parameters should be adjusted to produce significant damage to abnormal vascular tissue without significant damage to the surrounding tissue or, on the other hand, to enable the observation of blood vessels in the eye without significant damage to the surrounding tissue. Typically, the dose of texaphyrin of the texaphyrin-lipophilic molecule conjugate or texaphyrin-lipophilic molecule-vesicle complex used is within the range of from about 0.1 to about 50 $\mu\text{mol}/\text{kg/treatment}$, and preferably from about 0.10-20 $\mu\text{mol}/\text{kg/treatment}$. Further, as the texaphyrin dose is reduced, the fluence required to treat neovascular tissue may 10 change.

After the photosensitizing texaphyrin-lipophilic molecule conjugate or texaphyrin-lipophilic molecule-vesicle complex has been administered, the tissue being treated in the eye is irradiated at the wavelength of maximum absorbance of the texaphyrin, usually either about 400-500 nm or about 700-800 nm. The light source 15 may be a laser, a light- emitting diode, or filtered light from, for example, a xenon lamp; the light may have a wavelength range of about 400-900 nm, preferably about 400-500 nm or 700-800 nm, more preferably about 730-770 nm; and the light may be administered topically, endoscopically, or interstitially (via, e.g., a fiber optic probe). Preferably, the light is administered using a slit-lamp delivery system. A wavelength in 20 this range is especially preferred since blood and retinal pigment epithelium are relatively transparent at longer wavelengths and, therefore, treatment results in less tissue damage and better light penetration. The fluence and irradiance during the irradiating treatment can vary depending on type of tissue, depth of target tissue, and the amount of overlying fluid or blood.

25 The optimum length of time following texaphyrin-lipophilic molecule conjugate or texaphyrin-lipophilic molecule-vesicle complex administration until light treatment can vary depending on the mode of administration, the form of administration, and the type of target tissue. For example, a time interval of minutes to about 5 h should be appropriate for vascular tissue. The time of light irradiation after administration may be 30 important as one way of maximizing the selectivity of the treatment, thus minimizing damage to structures other than the target tissues. For a human, it is believed that the texaphyrin-lipophilic molecule conjugate or texaphyrin-lipophilic molecule-vesicle

complex begins to reach the retinal and choroidal vasculature within seconds following administration, and persists for a period of minutes to hours, depending on the dose given. Treatment within the first five minutes following administration should generally be activated with focused light. At later time points, both focused or general 5 illumination may be used.

In addition, texaphyrin-lipophilic molecule conjugate or texaphyrin-lipophilic molecule-vesicle complex can be used to observe the condition of blood vessels as a single agent, or in concert with other dyes such as fluorescein or indocyanine green to follow the progress of destruction of abnormal vascular tissue. In such angiographic 10 systems, a sufficient amount of texaphyrin-lipophilic molecule conjugate or texaphyrin-lipophilic molecule-vesicle complex is administered to produce an observable fluorescent emission when excited by light, preferably light having a wavelength in the range of about 430-480 nm. Images are recorded by illuminating the eye with light in the excitation wavelength range and detecting the amount of fluorescent light emitted at 15 the emission wavelength of about 730-760 nm. A preferred device, which both emits and receives light in the 430-760 nm range, is the TOPCONTM 50VT camera in the Ophthalmic Imaging System (Ophthalmic Imaging System Inc., 221 Lathrop Way, 20 Suite 1, Sacramento CA).

A camera is used to collect the emitted fluorescent light, digitize the data, and 20 store it for later depiction on a video screen, as a hard paper copy, or in connection with some other imaging system. While a film recording device may be used when additional dyes such as fluorescein are being used in combination with the texaphyrin-lipophilic molecule conjugate or texaphyrin-lipophilic molecule-vesicle complex, a 25 CCD camera (charge-coupled device) is preferable as being able to capture emissions at higher wavelengths. As a result, one can obtain more sophisticated information regarding the pattern and extent of vascular structures in different ocular tissue layers, giving the ability to detect the "leakiness" that is characteristic of new or inflamed blood vessels. Further, it is preferable to use a camera that is capable of providing the 30 excitation light, appropriately filtered to deliver only light of the desired excitation wavelength range, and then to capture the emitted, fluorescent light with a receiving device, appropriately filtered to receive only light in the desired emission wavelength range.

For the above-described uses, texaphyrin-lipophilic molecule-cell or -liposome complexes are provided as pharmaceutical preparations. A pharmaceutical preparation of such a complex may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers 5 include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. The pharmaceutical compositions formed by combining a complex of the present invention and the pharmaceutically acceptable carriers are then easily administered in a variety of dosage forms such as injectable solutions.

For parenteral administration, suspensions of the liposomal complex in sesame 10 or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be 15 employed will be known to those of skill in the art in light of the present disclosure. Intravenous administration of loaded red or white blood cell complexes of the present invention is contemplated as the most preferred method of administration.

Sterile technique is used for removal of cells from a patient, loading with a sterile texaphyrin-lipophilic molecule conjugate and replacement of loaded cells into the 20 same patient. A pharmaceutically acceptable carrier may be used, which carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, and by the use of surfactants. The 25 prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars such as mannitol or dextrose or sodium chloride. A more preferable isotonic agent is a mannitol solution of about 2-8% concentration, and, most 30 preferably, of about 5% concentration.

Sterile conjugate solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients

enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of
5 sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and
10 absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

15 For fluorescent detection methods of the present invention, a sufficient amount of texaphyrin is administered to produce an observable fluorescent emission when excited by light, preferably light having a wavelength in the range of about 430-480 nm. Images are recorded by illuminating with light in the excitation wavelength range and detecting the amount of fluorescent light emitted at the emission wavelength of
20 preferably about 730-760 nm. Such dose can be determined without undue experimentation by methods known in the art or as described herein.

25 The complexes to be used in the photodynamic methods of the present invention are administered in a pharmaceutically effective amount. By "pharmaceutically effective" is meant that dose which will, upon exposure to light, cause disruption of the loaded vesicle. The specific dose will vary depending on the particular complex chosen, the dosing regimen to be followed, photoirradiation exposure, and timing of administration. Such dose can be determined without undue experimentation by methods known in the art or as described herein.

30 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to

constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

5

EXAMPLE 1

Synthesis of a Texaphyrin-Lipophilic Molecule Conjugate

The present example provides the synthesis of a texaphyrin-lipophilic molecule conjugate where the lipophilic molecule is estradiol. The synthetic route is provided by Schematic A.

10

Penta(ethyleneglycol) diiodide (2). Penta(ethyleneglycol) ditosylate 1 (25 g, Aldrich Chemical, Milwaukee, WI), sodium iodide (17.15 g, 2.5 eq.), and acetone (ca. 500 mL) were combined and heated at reflux for 4 hours. Upon cooling, solids were removed by filtration and washed with acetone. Acetone was removed from the combined filtrate and washed by rotary evaporation. The resulting solid was dissolved in CHCl₃ (250 mL), and washed with water (250 mL), a 5% aqueous solution of Na₂S₂O₃ (2 X 250mL) and water (250 mL). Solvent was removed by rotary evaporation and the resulting solid dried *in vacuo* to give diiodide 2 (19.164 g, 91.3%).


3-(2-(Ethoxy-2-(ethoxy-2-(ethoxy-(2-iodoethoxy))))ethoxy)17β-hydroxy-3-oxy-1,3,5(10)-estratriene (4). The diiodide 2 (12.50 g), β-estradiol 3 (2.500 g, Aldrich Chemical, Milwaukee, WI), potassium carbonate (1.500 g) and anhydrous acetonitrile (250 mL) were combined in a flask. The reaction mixture was heated at reflux for 9 hours, whereupon it was allowed to cool in ambient temperature, and solvent removed by rotary evaporation. The residue was dissolved in CHCl₃ (125 mL), washed with water, and solvent removed by rotary evaporation. The crude product was purified by silica gel chromatography using 0.5 to 1.0% MeOH in CHCl₃ as eluent. Fractions containing only product were combined, solvent was removed by rotary evaporation, and the residue dried *in vacuo* to give iodide 4 (2.010 g, 36.4%).

Dinitrobenzene sodium salt (5), method one. The dinitrobenzene sodium salt 5 was prepared by reacting 4,5-dinitrocatechol (5 g, 0.025 mol) and triethylene glycol monomethyl ether monotosylate (11.9 g, 0.037 mol, 1.5 eq.) with K₂CO₃ (5.18 g, 0.037 mol, 1.5 eq.) in methanol, with heating to reflux under nitrogen atmosphere overnight. The reaction was allowed to cool to RT, and the solvent was removed under reduced


pressure. The residue was then resuspended into 250 mL of 1M NaOH, after which chloroform was added. The lower chloroform layer plus precipitate were drained off and the orange solid precipitate was collected by filtration and vacuum dried under high vacuum overnight to give the light orange solid product 5, in 81% yield.


5 *Dinitrobenzene Sodium Salt (5), method two.* An alternate method of synthesis of the dinitrobenzene sodium salt is as follows. In a dry 250 mL round bottom flask, 4,5-dinitrocatechol (10 g, 0.050 mol) and K₂CO₃ (10.37 g, 0.075 mol) were combined in absolute methanol (120 mL) under nitrogen atmosphere. To the orange mixture, triethylene glycol monomethyl ether tosylate (23.85 g, 0.075 mol) was added and the 10 resulting suspension was heated to reflux. The reaction was deemed complete by TLC analysis by the disappearance of the starting catechol and appearance of the bright yellow monoalkylated intermediate. Therefore, after 16 h the red suspension was cooled to 0°C. The resulting suspension was filtered, washed thoroughly with cold isopropyl alcohol (50 mL) and hexanes (50 mL). The monoalkylated potassium salt 15 was then suspended in 10% aqueous NaOH (100 mL), vigorously stirred for 15-20 min at room temperature, filtered, and then rinsed thoroughly with cold isopropyl alcohol (70 mL) and hexanes (50 mL). (This step aids the removal of excess K₂CO₃ and potassium tosylate). The bright orange salt was dried *in vacuo* and afforded 15 g (~81%). ¹H NMR (d₆ acetone): selected peaks, δ 3.40 (OMe), 6.30 (ArH), 7.42 (ArH); 20 EI MS (M + Na⁺) 369; EI HRMS (M + Na⁺) 369.0910 (calcd. for C₁₃H₁₈N₂O₉Na 369.0910).

Schematic A.



Schematic A. (con't)



Schematic A. (con't)

3-(2-(*Ethoxy*-2-(*ethoxy*-2-(*ethoxy*-(2-(1-*oxy*-2-(2-(*ethoxy*-2-(*ethoxy*-(2-*methoxy))))*ethoxy*)-4,5-dinitrobenzene)*ethoxy*))))*ethoxy*)-17 β -*hydroxy*-3-*oxy*-1,3,5(10)-*estratriene* (6). The iodide 4 (500 mg) and the sodium salt of 1-*hydroxy*-2-(2-(*ethoxy*-2-(*ethoxy*-(2-*methoxy))))*ethoxy*)-4,5-dinitrobenzene 5 (336 mg, 1.1 eq.) and acetonitrile (5 mL) were combined in a flask and the reaction mixture was heated at reflux overnight. Potassium carbonate (126 mg, 1.1 eq.) was added, and heating continued for ca. four hours. The reaction mixture was transferred to a separatory funnel with CHCl₃ (ca 25 mL), washed with water (2 X 15 mL), solvent removed on a rotary evaporator, and the residue dried overnight *in vacuo*. The crude product was purified by silica gel chromatography using 2% MeOH in CHCl₃ as eluent. Fractions containing only product were combined, solvent was removed by rotary evaporation, and the residue dried *in vacuo* to give 6 as a yellowish solid (549 mg, 80.5%). FAB: MH⁺821.**

Using known chemistry for the synthesis of texaphyrins (see the texaphyrin patents previously incorporated by reference herein) the dinitro compound 6 was reduced to the diamine 7 using an atmospheric pressure hydrogenation with 10% Pd on charcoal and 2 eq. of conc. HCl. The reduction was usually complete in 1-2 h. Afterwards, the catalyst was filtered off using a pad of Celite, the diamine solution was diluted with methanol, 1 equivalent of diformyl tripyrrane 8 was added, and the reaction was heated to reflux under nitrogen. The reaction started immediately after the addition of diformyl tripyrrane and was usually complete in 1-3 hr. Proton and carbon NMR of the resulting non-aromatic macrocycle 9 was consistent with structure. The non-aromatic macrocycle 9 was oxidatively metallated using 1.5 equiv.s of either lutetium acetate or gadolinium acetate and 10 equiv.s of triethylamine under air atmosphere to give the lutetium estradiol complex 10 (in 38% yield with a relative purity of 89%) or the gadolinium estradiol complex 11 (in 47% yield with a relative purity of 91%), respectively.

The synthesis of a texaphyrin-cholesterol conjugate is carried out in a similar manner using cholesterol instead of estradiol.

EXAMPLE 2
Loading Red Blood Cells with a
Texaphyrin-Lipophilic Molecule Conjugate

5 The present example provides for the loading of red blood cells with a texaphyrin-estradiol conjugate. Red blood cells (RBC's) were successfully loaded with gadolinium texaphyrin-estradiol conjugate 11 ("GTE") following an osmotic challenge to the red blood cells. Subsequently, UV/Vis spectra revealed that most of the conjugate was contained within the cell wall of the red blood cells.

10 For the studies below, the following general procedure was used: Whole blood from rabbit was collected in the presence of heparin and centrifuged. The serum layer was removed, and the RBC's were resuspended in saline (138 mM NaCl), and washed three times. After the third wash, the pelleted RBC's were resuspended in hypertonic saline (268 mM NaCl). The cells were mixed gently, held approximately 3 min at room 15 temperature, and centrifuged. The pelleted RBC's were resuspended in three volumes of hypotonic saline (110 mM NaCl) containing GTE to give Gd texaphyrin-estradiol-red blood cell complex.

20 I. In a first study, 300 mL of pelleted RBC's were resuspended in 1.0 mL of 110 mM NaCl with 0.2 or 0.4 mmoles of GTE. The cells were mixed gently and sonicated. After three washes, the pellet of GTE-RBC complex (300 mL) was resuspended with saline to a total volume of 2.0 mL. To determine the GTE content, 750 mL of this 2.0 mL solution were removed, 250 mL of fresh saline was added, and the optical density was read on a spectrophotometer. A control cuvette contained an equivalent mass and volume of RBC's treated similarly but without GTE. The O.D. of the 2.0 mL solution 25 was 0.9859, which indicated a yield of 120 mg total GTE complex (T2BET2, 732 nm, a 15.35 mg/mL solution has an O.D. of 0.3291).

20 II. In a second study, two different amounts of a stock solution of 2mM GTE in 5% mannitol were used; 1.6 mL with 4.0 mL packed RBC's, and 6.6 mL with 5.5 mL packed RBC's. To prepare the respective complexes, the RBC's were washed as described previously, the respective volumes of RBC's were resuspended with hypertonic saline to a total volume of 50 mL and centrifuged. The supernatant was removed and solutions of hypotonic saline with GTE were added so as to keep the volume at 40 mL. The suspensions were treated as described above and the final washed RBC's were suspended in a volume of 15 mL with normal saline and transferred

to 100 X 17 mm tubes to be analyzed by MRI (see, Example 3) (for the 1.6 mL reaction, 11 mL of saline; for the 6.6 mL reaction, 9.5 mL of saline; the control was 5.0 mL packed RBC's and 10 mL of saline).

III. In a further study, RBC's were loaded with GTE to be used as an injectable
5 into rabbits. Packed RBC's (5.0 mL, washed as described) were treated with hypertonic saline and 40 mL total volume of hypotonic saline with 6.0 mL GTE. After sonication, the cells were washed 3 times and resuspended with 2.5 mL of normal saline. The resulting complex was used for injection into rabbits (see, Example 4).

10

EXAMPLE 3

In Vitro Imaging with GdT2BET-Estradiol-Red Blood Cell Complex

The present example provides *in vitro* magnetic resonance imaging (MRI) results with GTE-RBC complex.

Packed or resuspended red blood cell complexes were imaged using a GE 0.5T
15 Signa magnetic resonance imager (GE Medical Systems, Milwaukee, WI) and the following parameters: pulse sequences, spin echo 350/15; acquisition parameters, 20FOV, 256X256; slice thickness/space, 5mm/2.5mm; and nex, 2.

Table 2 provides MRI values using GTE-RBC complex (from Example 2, II). CuSO₄ is an imaging standard that allows the intensity (whiteness) of the signal to be
20 gauged.

TABLE 2. MRI Values of GdT2BET-Estradiol-Red Blood Cell Complexes

Sample	RBC Control	RBC with 3.2mmol GTE	RBC with 13.2mmol GTE	Saline control	CuSO ₄ Standard
Packed GTE-RBC Complexes	818	1386	1405	311	1181
	793	1354	1514	309	1166
Average	805.5	1370	1459.5	310	1173.5
Resuspended GTE-RBC Complexes	530	876	2095	298	1144
	496	800	2084	280	1103
	487	793	2105	270	1095
Average	504.333333	823	2094.666667	282.67	1114

5 Approximately 8.3 μ mol GTE was incorporated in 5 ml of packed red cells using this method.

EXAMPLE 4

***In Vivo* Imaging with GdT2BET-Estradiol-Red Blood Cell Complex**

10 The present example demonstrates magnetic resonance imaging of an animal using GTE-RBC complexes. MRI scans revealed contrast enhancement of tissues and enhanced angiograms for up to 30 min after injection.

15 A New Zealand white rabbit (2.72 kg) having a V2 carcinoma tumor implanted in each thigh was injected with 7 mL of GTE-RBC complex and a normal New Zealand white rabbit (3 kg) was also injected with the same amount of the complex as a control. The rabbit having the tumors died after 2.5 mL of the complex was injected. The rabbit appeared to be already very sick from the cancer. The normal rabbit was scanned pre-contrast, immediately post-injection, and 30 min after injection. The rabbit was positioned supine inside a knee coil and entered the magnetic field feet first. The rabbit was anesthetized and maintained with ketamine/Rompun cocktail during MRI. The 20 scan parameters were as in Example 3 with the acquisition parameter being 256X160 for this animal study and the MR angiogram scanning technique was 2D TOF for the aorta.

The normal rabbit had good liver and angiogram enhancement for at least 30 min after injection of the GTE-RBC complex.

EXAMPLE 5

5

Photodynamic Therapy Using Photosensitive Texaphyrin-Lipophilic Molecule-Loaded-Vesicles

The present example provides for the light-dependent lysis of loaded vesicles, such as red blood cells or liposomes, and the consequent deposition of the contents at 10 the irradiated site. When irradiated with light of an appropriate wavelength, vesicles loaded with a photosensitive texaphyrin will lyse.

The effect of PDT with photosensitive texaphyrin-loaded vesicles is multifaceted in that specificity is provided by the biolocalization of the vesicle, a PDT effect is seen in the vicinity of the deposited texaphyrin due to singlet oxygen product 15 toxicity, and if a therapeutic agent is incorporated into the vesicle in addition to the texaphyrin, the therapeutic agent is deposited at a target site. A chemotherapeutic drug may be delivered to a target site in this manner, for example.

A preferred photosensitive texaphyrin is a lutetium texaphyrin, for example, compound 1_B as described herein. In the present light-dependent lysis, the light may 20 have a wavelength range of about 650-900 nm, preferably 700-800 nm, and most preferably 730-770 nm.

EXAMPLE 6

25

Liposomes Comprising a Texaphyrin-Lipophilic Molecule Conjugate

The present example provides for the incorporation of a texaphyrin-lipophilic molecule conjugate into liposomes and liposomal-like particles.

A texaphyrin-lipophilic molecule conjugate may be incorporated into small unilamellar liposomes as follows, for example. Egg phosphatidylcholine conjugated 30 with ethylene glycol and cholesterol (8:2 molar ratio) are suspended in chloroform and a 33% molar concentration of texaphyrin-lipophilic molecule conjugate is added to the solution. The chloroform is evaporated under vacuum and the dried material is resuspended in phosphate buffered saline (PBS). The mixture is transferred to a cryovial, quick frozen in liquid nitrogen, and thawed five times. The material is then

extruded through an extruder device (Lipex Biomembranes, Vancouver, B.C., Canada) 5 times using a 400 nm diameter pore size polycarbonate filter to produce 400 nm liposomes. A portion of the 400 nm liposomes is extruded through 100nm diameter filters 10 times to produce 100 nm liposomes. A portion of the 100 nm liposomes is then extruded 10 times through 15 nm filters, producing liposomes of 30 nm size.

10 Liposomes prepared as described above may also be subjected to a Microfluidizer (Microfluidics, Newton, Mass.). Specifically, liposomes may be passed 10 times through the microfluidizer at a pressure of 16,000 psi and a flow rate of 450 mL/min. The resulting liposomes are expected to have a mean average size of 30-40nm, which may be verified by Quasi Elastic Light Scattering.

15 A texaphyrin-lipophilic molecule conjugate incorporated in this way into liposomes may be physically inside the liposome, incorporated into the lipid bilayer of the liposome, or incorporated in such a way that part of the conjugate is outside of the liposome. A liposome incorporating a texaphyrin-lipophilic molecule can be stabilized using ethylene glycol to slow its uptake by phagocytic white blood cells.

EXAMPLE 7

Induction of Antibody Formation Using Texaphyrin-Lipophilic Molecule-Loaded-Red Blood Cells or -Liposomes

20 In addition to conventional methods known to those of skill in the art of immunology for making antibodies having a particular binding specificity, antibodies having binding specificity for a texaphyrin molecule may be induced in a host that has been administered a texaphyrin-lipophilic molecule loaded-red blood cell or -liposome. Further, if the loaded cell also contains an immunogen, antibodies may be generated 25 having binding specificity for that immunogen.

30 Using a photosensitive texaphyrin, light will lyse such a loaded red blood cell or liposome causing release of its contents within a host. Consequent exposure of the host to an immunogen contained therein would induce antibody formation to the immunogen. Candidate immunogens may include, but are not limited to, surface HIV proteins, such as gp 120, for example. This method would be particularly effective using a loaded cell from an animal different than the animal injected, for example, using loaded goat red blood cells for injection into a rabbit. The goat cells may act as adjuvant in this case.

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may 5 be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, 10 scope and concept of the invention as defined by the appended claims.


CLAIMS:

1. A texaphyrin-lipophilic molecule-vesicle complex.
2. The complex of claim 1 wherein the vesicle portion of the complex is a biological cell.
3. The complex of claim 1 wherein the vesicle portion of the complex is a liposome.
- 5 4. The complex of claim 1 wherein the lipophilic molecule portion of the complex is estradiol or cholesterol.
5. The complex of claim 2 wherein the biological cell is a red blood cell.
6. The complex of claim 1 wherein the texaphyrin-lipophilic molecule portion of the complex has structure I:

10

15

20



I

wherein

M is a divalent or trivalent metal cation;

25 **R₁-R₄, R₅ and R₆** are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, a lipophilic molecule, or a couple that is coupled to a lipophilic molecule;

R₆ and **R₉** are independently selected from the groups of **R₁-R₄**, **R₇** and **R₈**, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;


R₅ and **R_{10-R₁₂}** are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, or a couple that is coupled to a saccharide, or to a lipophilic molecule;

5 **n** is an integer value less than or equal to 5; and

10 wherein at least one of **R_{1-R₁₂}** is a lipophilic molecule or a couple that is coupled to a lipophilic molecule.

7. The complex of claim 1 wherein the texaphyrin-lipophilic molecule portion of the complex has structure **II**:

15



20

II

wherein

25 **R_{1-R₄}**, **R₇** and **R₈** are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, a lipophilic molecule, or a couple that is coupled to a lipophilic molecule;

30 **R₆** and **R₉** are independently selected from the groups of **R_{1-R₄}**, **R₇** and **R₈**, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;

R₅ and **R₁₀-R₁₂** are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, or a couple that is coupled to a saccharide, or to a lipophilic molecule;

5 **R₁₃** is alkyl, alkenyl, oxyalkyl, or hydroxyalkyl having up to about 3 carbon atoms and having rotational flexibility around a first-bound carbon atom; and wherein at least one of **R₁-R₁₂** is a lipophilic molecule or a couple that is coupled to a lipophilic molecule.

8. The complex of claim 6 wherein **R₁** is CH₂(CH₂)₂OH, **R₂** and **R₃** are CH₂CH₃, **R₄** is CH₃, **R₇** is O(CH₂CH₂O)₃CH₃, **R₈** is a couple that is coupled to estradiol, and **R₅, R₆, and R₉-R₁₂** are H.

10 9. The complex of claim 6 wherein **R₁** is CH₂(CH₂)₂OH, **R₂** and **R₃** are CH₂CH₃, **R₄** is CH₃, **R₇** is O(CH₂CH₂O)₃CH₃, **R₈** is a couple that is coupled to cholesterol, and **R₅, R₆, and R₉-R₁₂** are H.

15 10. A texaphyrin-lipophilic molecule conjugate.

11. The conjugate of claim 10 wherein the lipophilic molecule portion of the conjugate is estradiol.

12. The conjugate of claim 10 wherein the lipophilic molecule portion of the conjugate is cholesterol.

20 13. A method for delivery of an agent to a targeted biological site, comprising: loading a vesicle with a photosensitive texaphyrin-lipophilic molecule conjugate and the agent to form a texaphyrin-lipophilic molecule-vesicle complex; allowing the complex to locate at the targeted biological site; and photoirradiating the complex,

25 wherein the complex is lysed by photoirradiating, thereby delivering the agent to the targeted biological site.

14. A method for delivery of naturally occurring cellular contents of a cell to a targeted biological site, comprising:

loading the cell with a photosensitive texaphyrin-lipophilic molecule conjugate to form a texaphyrin-lipophilic molecule-cell complex;

allowing the complex to locate at the targeted biological site; and

photoirradiating the complex,

5 wherein the complex is lysed by photoirradiating, thereby delivering naturally occurring cellular contents of the cell to the targeted biological site.

15. A method for photodynamic therapy, comprising:
administering a photosensitive texaphyrin-lipophilic molecule-vesicle complex to a subject; and
photoirradiating the complex.

10

16. The method of claim 13 wherein the agent is a photodynamic therapy agent, a chemotherapeutic agent, or a radiation sensitizing agent.

17. The method of claim 13, or 15 wherein the vesicle portion of the complex is a red blood cell.

15 18. The method of claim 13, 14, or 15 wherein the photosensitive texaphyrin portion of the conjugate includes a diamagnetic metal cation bound by the texaphyrin.

19. The method of claim 18 wherein the diamagnetic metal cation is Lu(III), La(III), In(III), Y(III), Zn(II) or Cd(II).

20. The method of claim 18 wherein the diamagnetic metal cation is Lu(III).

20 21. The method of claim 13, 14, or 15 wherein the lipophilic molecule portion of the conjugate is estradiol.

22. The method of claim 13, 14, or 15 wherein the lipophilic molecule portion of the conjugate is cholesterol.

25 23. The method of claim 13, 14, or 15 wherein the photoirradiating is with light having a wavelength range of about 700 to 900 nanometers.

24. The method of claim 13, 14, or 15 wherein the photoirradiating is with light having a wavelength range of about 700-800 nanometers.


25. The method of claim 13, 14, or 15 wherein the phot sensitive texaphyrin is selected from the group consisting of texaphyrins A1-A108 of Tables A and B.

26. The method of claim 13, 14, or 15 wherein the vesicle portion of the complex is a red blood cell and the subject is a donor of the red blood cell.

5 27. The method of claim 13, 14, or 15 wherein the photosensitive texaphyrin-lipophilic molecule portion of the complex has structure I:

10

15



I

20 wherein

M is a diamagnetic metal cation;

R₁-R₄, R₇ and R₈ are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, a lipophilic molecule, or a couple that is coupled to a lipophilic molecule;

25

R₆ and R₉ are independently selected from the groups of R₁-R₄, R₇ and R₈, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;

30


R₅ and R₁₀-R₁₂ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl,

carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, or a couple that is coupled to a saccharide, or to a lipophilic molecule;
 n is an integer value less than or equal to 5; and
 wherein at least one of R_1 - R_{12} is a lipophilic molecule or a couple that is coupled to a
 5 lipophilic molecule.

28. The method of claim 13, 14, or 15 wherein the photosensitive texaphyrin-lipophilic molecule portion of the complex has structure II:

10

15



II

wherein

20 R_1 - R_4 , R_7 and R_8 are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, a lipophilic molecule, or a couple that is coupled to a lipophilic molecule;

25 R_6 and R_9 are independently selected from the groups of R_1 - R_4 , R_7 and R_8 , with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;

30 R_5 and R_{10} - R_{12} are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, or a couple that is coupled to a saccharide, or to a lipophilic molecule;

R_{13} is alkyl, alkenyl, oxyalkyl, or hydroxyalkyl having up to about 3 carbon atoms and having rotational flexibility around a first-bound carbon atom; and wherein at least one of R_1-R_{12} is a lipophilic molecule or a couple that is coupled to a lipophilic molecule.

- 5 29. A method of imaging a subject, comprising:
administering a detectable texaphyrin-lipophilic molecule-vesicle complex to a subject; and
scanning the subject to obtain a visible image of an internal region of the subject.
30. The method of claim 29 wherein the detectable texaphyrin is a fluorescent texaphyrin
10 and scanning is by observing fluorescence of the texaphyrin.
31. The method of claim 29 wherein the detectable texaphyrin is complexed with a paramagnetic metal cation and scanning is by magnetic resonance imaging of the texaphyrin.
32. The method of claim 29 wherein the visible image is of a blood pool or of a blood
vascular system.
- 15 33. The method of claim 29 wherein the vesicle portion of the complex is a red blood cell and the subject is a donor of the red blood cell.
34. A method of producing an antibody having binding specificity for a texaphyrin in a subject comprising:
administering a photosensitive texaphyrin-lipophilic molecule-vesicle complex to the
20 subject; and
photoirradiating the complex
wherein photoirradiating exposes the texaphyrin to the subject, thereby inducing formation of an antibody having binding specificity for texaphyrin.
35. The method of claim 34 wherein the complex is further loaded with an agent, and
irradiating exposes the agent to the subject thereby inducing formation of an antibody having
25 binding specificity for the agent.
36. An antibody having binding specificity for a photosensitive texaphyrin molecule.

37. Use of a texaphyrin-lipophilic molecule conjugate in the preparation of a pharmaceutical composition for use in membrane incorporation for diagnosis or treatment of a human subject.

38. Use of a texaphyrin-lipophilic molecule-vesicle complex in the preparation of a pharmaceutical composition for use in membrane incorporation for diagnosis or treatment of a human subject.

39. The use of claim 37 or 38 wherein the use is treatment of the human subject and the treatment is photodynamic therapy.


40. The use of claim 37 or 38 wherein the use is treatment of the human subject and the treatment is delivery of a chemotherapeutic or radiosensitization agent.

41. The use of claim 37 or 38 wherein the use is diagnosis of the human subject and the diagnosis is imaging of the human subject.

42. The use of claim 41 wherein the diagnosis is angiography.

43. The use of claim 39 wherein the treatment is photodynamic therapy for macular degeneration or neovascularization of the eye.

44. The use of claim 37 or 38 wherein the texaphyrin-lipophilic molecule has structure I:



I

wherein

M is a divalent or trivalent metal cation;

R₁-**R**₄, **R**₇ and **R**₈ are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, a lipophilic molecule, or a couple that is coupled to a lipophilic molecule;


5 **R**₆ and **R**₉ are independently selected from the groups of **R**₁-**R**₄, **R**₇ and **R**₈, with the proviso that the halide is other than iodide and the haloalkyl is other than 10 iodoalkyl;

R₅ and **R**₁₀-**R**₁₂ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, or a couple that is coupled to a saccharide, or to a lipophilic molecule;

15 **n** is an integer value less than or equal to 5; and

wherein at least one of **R**₁-**R**₁₂ is a lipophilic molecule or a couple that is coupled to a lipophilic molecule.

45. The use of claim 37 or 38 wherein the texaphyrin-lipophilic molecule has structure **II**:



II

30 wherein

R₁-**R**₄, **R**₇ and **R**₈ are independently hydrogen, halide, hydroxyl, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy,

hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, a lipophilic molecule, or a couple that is coupled to a lipophilic molecule;

5 **R₆** and **R₉** are independently selected from the groups of **R₁-R₄**, **R₇** and **R₈**, with the proviso that the halide is other than iodide and the haloalkyl is other than iodoalkyl;

10 **R₅** and **R_{10-R₁₂}** are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxamide, carboxamidealkyl, amino, aminoalkyl, or a couple that is coupled to a saccharide, or to a lipophilic molecule;

15 **R₁₃** is alkyl, alkenyl, oxyalkyl, or hydroxyalkyl having up to about 3 carbon atoms and having rotational flexibility around a first-bound carbon atom; and wherein at least one of **R_{1-R₁₂}** is a lipophilic molecule or a couple that is coupled to a lipophilic molecule.

46. The use of claim 37 or 38 wherein the texaphyrin is selected from the group consisting of texaphyrins A1-A108 of Tables A and B.

47. The use of claim 44 wherein **R₁** is $\text{CH}_2(\text{CH}_2)_2\text{OH}$, **R₂** and **R₃** are CH_2CH_3 , **R₄** is CH_3 , **R₇** is $\text{O}(\text{CH}_2\text{CH}_2\text{O})_3\text{CH}_3$, **R₈** is a couple that is coupled to estradiol, and **R₅**, **R₆**, and **R_{9-R₁₂}** are H.

20 48. The use of claim 44 wherein **R₁** is $\text{CH}_2(\text{CH}_2)_2\text{OH}$, **R₂** and **R₃** are CH_2CH_3 , **R₄** is CH_3 , **R₇** is $\text{O}(\text{CH}_2\text{CH}_2\text{O})_3\text{CH}_3$, **R₈** is a couple that is coupled to cholesterol, and **R₅**, **R₆**, and **R_{9-R₁₂}** are H.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48, 41/00		A3	(11) International Publication Number: WO 97/46262 (43) International Publication Date: 11 December 1997 (11.12.97)
<p>(21) International Application Number: PCT/US97/09501</p> <p>(22) International Filing Date: 4 June 1997 (04.06.97)</p> <p>(30) Priority Data: 08/657,947 4 June 1996 (04.06.96) US</p> <p>(71) Applicants (for all designated States except US): PHARMACYCLICS, INC. [US/US]; 995 East Arques Avenue, Sunnyvale, CA 94086-4521 (US). BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): YOUNG, Stuart, W. [US/US]; 45 Las Piedras, Portola, CA 94028 (US). WRIGHT, Meredith [US/US]; 1057 Ginger Lane, San Jose, CA 95128 (US). SESSLER, Jonathan, L. [US/US]; 5005 Crestway Drive, Austin, TX 78712 (US). MODY, Tarak, D. [US/US]; 243 Buena Vista Avenue #206, Sunnyvale, CA 94086 (US). MAGDA, Darren [US/US]; 10237 University Way, Cupertino, CA 95014 (US).</p> <p>(74) Agent: NORBERG, Gloria, L.; Akin, Gump, Strauss, Hauer & Feld, L.L.P., Suite 1900, 816 Congress Avenue, Austin, TX 78701 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> <p>(88) Date of publication of the international search report: 12 March 1998 (12.03.98)</p>	
<p>(54) Title: MEMBRANE INCORPORATION OF TEXAPHYRINS</p> <p>(57) Abstract</p> <p>Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen. By presenting the agent in this way, it is expected that a patient will experience less toxicity.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CI	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 97/09501

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48 A61K41/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCHENNING A P H J ET AL: "AN AMPHIPHILIC PORPHYRIN WITH UNEXPECTED AGGREGATION BEHAVIOUR" TETRAHEDRON LETTERS, vol. 34, no. 44, 29 October 1993, pages 7077-7080, XP000403174 see abstract ---	1-48
A	WO 92 05109 A (UNIV TEXAS) 2 April 1992 see claims 1,11,17 ---	1-48
P,A	US 5 591 422 A (HEMMI GREGORY W ET AL) 7 January 1997 see column 9, line 43 - line 52 see column 15, line 41 - column 16, line 24 see column 10, line 22 - line 25; claims --- -/-	1-48

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "a" document member of the same patent family

1

Date of the actual completion of the international search

26 January 1998

Date of mailing of the international search report

- 4. 02. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 apo nl
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/09501

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 10307 A (UNIV TEXAS ;PHARMACYCLICS INC (US); SESSLER JONATHAN L (US); HARRI) 20 April 1995 see page 20, line 18 - page 21, line 34 see page 12, line 1 - line 8 --- KOENIG K ET AL: "PDT OF TUMOR-BEARING MICE USING LIPOSOME DELIVERED TEXAPHYRINS" PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON PHOTODYNAMIC THERAPY AND MEDICAL LASER APPLICATIONS, 24 June 1992, pages 802-805, XP000611944 see abstract --- WO 95 21845 A (UNIV TEXAS ;PHARMACYCLICS INC (US); SESSLER JONATHAN L (US); MODY) 17 August 1995 see page 7, line 8 - line 16 -----	1-48
A		1-48
1		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/09501

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 13-35 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat	l Application No
	PCT/US 97/09501

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9205109 A	02-04-92	US 5120411 A AT 127098 T AU 7072391 A DE 69022073 D DE 69022073 T EP 0515404 A	09-06-92 15-09-95 15-04-92 05-10-95 22-02-96 02-12-92
US 5591422 A	07-01-97	US 5599928 A US 5601802 A	04-02-97 11-02-97
WO 9510307 A	20-04-95	US 5457183 A AU 683316 B AU 8075694 A CA 2173319 A EP 0724457 A JP 9508616 T NO 961436 A US 5599923 A US 5622946 A US 5583220 A US 5580543 A US 5587371 A US 5632970 A	10-10-95 06-11-97 04-05-95 20-04-95 07-08-96 02-09-97 11-06-96 04-02-97 22-04-97 10-12-96 03-12-96 24-12-96 27-05-97
WO 9521845 A	17-08-95	US 5599923 A AU 1921795 A CA 2182960 A EP 0745085 A NO 963396 A US 5599928 A	04-02-97 29-08-95 17-08-95 04-12-96 14-10-96 04-02-97